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Abstract   
Orthopedic tissue regeneration would benefit the aging population or patients with 
large osteoporotic large bone fracture and degenerative cartilage diseases, especially 
osteoarthritis (OA). Despite progress in surgical and pharmacological interventions, new 
regenerative approaches are needed to meet the challenge of restoring bone and articular 
cartilage tissues that are not only structurally sound but also functional. The following 
work explores two promising therapeutic strategies for orthopedic tissue regeneration: 
“ex vivo tissue engineering” to engineer bone tissue constructs with smart combinations 
of stem cells and biomaterials and “small molecule-based in vivo regenerative approach” 
to i) promote the chondrogenic potential of endogenous progenitor cells and ii) eliminate 
abnormal cells – senescent cells (SnCs) – that develop with OA. 
The ex vivo tissue engineering focused on the development of functional bone like-
tissue by co-culturing human induced pluripotent stem cells-derived osteoblasts (OB) and 
osteoclasts (OC) in hydroxyapatite (HA)-based three dimensional scaffolds. Results 
showed 3D bone model comprising both cell types promote bone formation compared to 
OB only cultures in a HA-dose dependent manner via coupling signals coordinating 
osteoblast and osteoclast activity and finely tuned expression of inflammatory molecules.  
The first small molecule approach for cartilage regeneration that was explored involved 
carbohydrate-based OA drug, tri-butanoylated N-acetyl-D-galactosamine analog, as a 
inducer of chondrogenic differentiation of hMSCs and inhibitor of inflammation. The 
second drug-based therapy is intra-articular (IA) injection of a senolytic molecule that 
selectively killed SnCs. This work explores the role of SnCs in the disease progression of 




development. It was found SnCs accumulate in the articular cartilage after anterior 
cruciate ligament transection (ACLT) and selective elimination of these cells attenuated 
the development of OA, reduced pain, and increased cartilage development. The three 
therapies presented in this dissertation represent viable strategies for bone and articular 
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Col2a1 CCTCCGTCTACTGTCCACTGA ATTGGAGCCCTGGATGAGCA 
Aggrecan (acan) CGTTGCAGACCAGGAGCAAT CGGTCATGAAAGTGGCGGTA 




ctsk GCACCCTTAGTCTTCCGCTC ACCCACATCCTGCTGTTGAG 
rankl GAGCACGAAAAACTGGTCGG AGGGTTGGACACCTGAATGC 
opg CAGCCATTTGCACACCTCAC TTAGAGATCTTGGCCCAGCC 
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Chapter 1: Introduction to Thesis 
1.1 Introduction  
Most of the current strategies in bone tissue engineering involve the cultivation of 
OB derived from human bone marrow MSCs on 3D alloplastic materials (primarily 
calcium phosphate, CaP) prior to re-implantation. However, this approach fails to 
emulate physiological bone regeneration involving a well-orchestrated series of cytokines 
and regulatory molecules secreted from immune cells, including monocytes, 
macrophages, and OC [1, 2]. We hypothesize that OB and OC—and their respective 
bone-building and -resorbing activities—must be balanced on bone-like synthetic 
scaffolds to create such bone substitutes. hiPSCs constitute an exciting prospective cell 
source for engineering bone [3], as they can generate patient- or disease-specific 
mesenchymal and monocyte/macrophage precursors that in turn differentiate into OBs 
and OCs, respectively. The purpose of Aim 1 is to engineer functional bone like-tissue 
constructs by co-culturing hiPSC-MSC and -macrophages. From a translational 
standpoint, our 3D tissue-engineered bone using patient-specific iPSCs could capture the 
functional interplay between osteoclastic and osteoblastic activities and thus, it could be 
used in understanding of bone cell phenotypes in the pathology of bone disease and in the 
testing of drugs regulating bone homeostasis. 
  OA is a chronic disease characterized by degeneration of cartilage tissue that lines 
articulating joint surfaces, leading to pain and physical disability [4]. Current 
pharmacologic OA treatment options are analgesics, non-steroidal anti-inflammatory 




treatments focus on short-term symptomatic pain relief and care of joint function[6], 
however with advances in the understanding of the OA pathogenesis there is a focus now 
on disease-modifying OA drugs (DMOADs) designed to block or reverse OA 
progression by targeting specific OA catabolic pathways and pathophysiological 
signaling pathways [7, 8].  
 The inflammatory cytokines and catabolic regulators present in an OA joint 
disrupt the chondrogenic differentiation capabilities of the MSCs and reduce cartilage 
regenerative capacity[9, 10]. Therefore, there is a critical need for small-molecules drug 
to not only reduce inflammation in the local joint environments but also rebuild cartilage 
tissue by creating favorable conditions for drugs to act on endogenous MSCs on the 
cartilage tissue. The goal of Aim 2 is to investigate a therapeutic effect of the new 
carbohydrate-based disease-modifying OA drug, tri-butanoylated N-acetyl-D-
galactosamine analog (3,4,6-O-Bu3GalNAc), for cartilage repair by inducing cartilage 
tissue production by human MSCs and inhibiting inflammatory response of human OA 
chondrocytes.  
  The incidence of OA correlates directly with aging and joint trauma, but the 
underlying mechanisms remain unclear, impeding the development of therapeutic 
interventions that might prevent or treat the disease. Cellular senescence, a mechanism 
that prevents proliferation of damaged and dysfunctional cells, protects against cancer 
development [11, 12] but also contributes significantly to cell and tissue deterioration that 
underlies age-related pathologies[13]. SnCs accumulate in tissues and organs with aging 
where they progressively disrupt organ structure and function, presumably through the 




extracellular matrix proteases, pro-inflammatory molecules, and growth factors [14]. 
While the accumulation of SnCs has been associated with OA [15, 16], the underlying 
mechanisms and details of SnCs impact on the OA progression – whether or which 
tissues in the arthritic joints become senescent, their kinetics of accumulation, and the 
removal of SnCs to attenuate or reverse OA. Thus, the goal of Aim 3 is to develop a novel 
pharmacological approach that aims to eliminate SnCs in a joint for cartilage 
regeneration.  
 
1.2 Specific Aims of thesis 
To achieve these goals, we propose the follow aims (Fig 1.1);  
 
Aim 1: Engineering bone tissue from hiPSC-derived osteoblast and osteoclast 
lineages in 3D biomaterials 
Hypothesis: Incorporation of hiPSC-macrophage and osteoclast responsible for bone 
matrix remodeling to osteoblasts accelerates the maturation of bone compared with 
osteogenic cells alone. 
Aim 2: Promoting chondrogenesis by local delivery of a sugar analog for cartilage 
repair   
Hypothesis: The sugar analog 3,4,6-O-Bu3GalNAc promotes chondrogenesis of human 
MSC and reduces inflammation of human OA chondrocytes by modulating Wnt/β-catenin 
signaling.  





Hypothesis: Trauma and aging induces SnCs in the articular joint and removal of SnCs 
in the model trauma-induced and aging-related OA reduces the disease progression of 







Figure 1.1 Schematic representation of two promising regenerative approaches for 
orthopedic tissues for bone and articular cartilage. ex vivo tissue engineering uses 
smart combination of stem cells, scaffold-based biomaterials and growth and 
differentiation factors (in Aim 1 in this dissertation) and small molecule-based in vivo 
regenerative approaches include targeting endogenous chondrocyte progenitor cells 
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Chapter 2. Engineering bone tissues from human iPSC-derived 
osteoblast and osteoclast lineages in 3D scaffolds  
2.1 Introduction  
 Bone grafting is required to facilitate repair and regeneration of bone defects 
resulting from severe fracture in elderly osteoporosis patients, trauma, tumor ablation, or 
congenital abnormalities. Autologous grafts are regarded as the current gold standard, but 
due to their significant limitations bone tissue engineering has been explored as a 
promising alternative to autologous grafts [1, 2]. Most of the current strategies in bone 
tissue engineering involve the cultivation of osteoblasts (OB) derived from human bone 
marrow mesenchymal stem cells (MSCs) on 3D alloplastic materials (primarily calcium 
phosphate, CaP) prior to re-implantation [3] (Fig 2.1). However, this approach fails to 
emulate physiological bone regeneration involving a well-orchestrated series of cytokines 
and regulatory molecules secreted from immune cells, including monocytes, 
macrophages, and osteoclasts (OC) (Fig 2.1). An orchestrated performance of these 
molecules is required to mimic functional and structural intricacies of native bone, to 
integrate with the host environment, and to establish mechanical stability of the bone 
substitutes [4, 5]. Thus, recreating the complex interplay between bone and immune cells 
in engineered substitutes may be necessary to create a functional tissue, rather than just to 
induce bone formation. We hypothesized that OBs and OCs—and their respective bone-
building and -resorbing activities—must be balanced on bone-like synthetic scaffolds to 




Human induced pluripotent stem cells (hiPSC) constitute an exciting prospective 
cell source for engineering bone, as they can generate patient- or disease-specific 
mesenchymal and monocyte/macrophage precursors that in turn differentiate into OBs 
and OCs, respectively [6] (Fig 2.2). hiPSCs have been differentiated into OBs on 2D 
plastic and 3D CaP scaffolds [7-11] and produced dense bone matrix on 3D decellurized 
bone scaffolds in a perfusion bioreactor [12]. OCs have been generated from hiPSCs on 
2D plastic and on mineralized substrates by embryonic body (EB) formation [13] and by 
co-culturing with stromal cells [14]. Nevertheless, to our knowledge, these derived OB 
and OC precursors have not been co-cultured to capture the functional coupling of bone 
resorption and formation that is typical of living bone.  
Taking cues from natural bone tissue, the goal of this study was to engineer 
functional bone like-tissue constructs by co-culturing hiPSC-MSC and hiPSC-
macrophages. Our previous work defined optimal scaffold compositions and tissue 
quality of bone engineered from human embryonic stem cells (hESC) [15, 16]. In the 
present work, we first differentiated hiPSC-derived MSCs and macrophages into 
osteogenic and osteoclastogenic lineages, respectively, and established a 3D model of 
human bone by co-culturing these cells within HA-based scaffolds. We then explored 
bone formation and resorption in vitro and in a subcutaneous implantation model. We 
also studied molecular changes to identify the coupling signals and inflammatory 





2.2 Materials and Methods  
EB formation from hiPSC 
The MJ hiPSC used in this study were derived from a healthy individual and have 
been previously described [17]. For embryoid body (EB) formation, hiPSC were 
detached from plates and transferred to six-well ultra-low-attachment plates. To 
differentiate three germ layers in vitro, EBs were maintained in EB culture medium for 
15–20 days with half of the medium changed every other day. EB medium consisted of 
DMEM-F12 (Invitrogen), 20% (v/v) Knockout Serum Replacement (Invitrogen), 1 mM 
L-glutamine, 0.1 mM β-mercaptoethanol (β-ME), and 1X nonessential amino acids 
(NEAA) [17]. 
Differentiation (adipogenic, chondrogenic, and osteogenic) and characterization of 
MSCs from hiPSCs  
To generate mesenchymal progenitors, the EBs were transferred onto tissue 
culture plates coated with gelatin (0.1% w/v) and cultured for 10 additional days until the 
outgrowth from the EBs occurred in MSC growth medium consisting of DMEM 
(Invitrogen) supplemented with 10% FBS (Hyclone), 1% Glutamax (Invitrogen), 100 
U/ml penicillin-streptomycin (Invitrogen), and 8 ng/mL basic fibroblast growth factor 
(bFGF) (PeproTech). Migrating cells isolated from EBs were subcultured at an initial cell 
density of 2 x 104 cells/cm2 and subsequently expanded as MSCs under the same 
conditions (3 - 5 passages used for all experiments).  
For adipogenic differentiation, we cultured the hiPSC-derived MSCs at 1 x 104 




penicillin-streptomycin, 1 µM dexamethasone, 100 µM indomethacin, 500 µM 3-
isobutyl-1-methtlxanthine (IBMX), and 10 µg/ml Insulin (all from Sigma). To evaluate 
adipogenesis, lipid droplets were stained with 30 mg/ml oil red O (Sigma-Aldrich) in 
60% isopropanol after fixation of cells with 10% formaldehyde.  
Chondrogenic differentiation of hiPSC-MSCs was evaluated in 3D micromass 
cultures. Cells (5 x 104) were seeded in the 96-well MicroWell™ round bottom plate 
(Thermo Fisher Scientific) and the 3D micromass was formed in the bottom by 
centrifuging at 2000 rpm for 5 min. The micromass was maintained at 37°C with 5% CO2 
in the chondrogenic media consisting of DMEM, 10% FBS, 100 U/ml penicillin-
streptomycin, 1% ITS premix (BD Bioscience), 100 mM sodium pyruvate (Life 
Technologies), 40 mg/ml L-proline (Sigma), 50 mM ascorbic acid-2-phosphate, and 10 
ng/mL of transforming growth factor-β1 (TGF-β1) (PeproTech). To evaluate 
chondrogenesis, the micromass was harvested after 4 weeks, fixed in 4% 
paraformaldehyde overnight, dehydrated in increasing concentrations of ethanol, 
embedded with paraffin, and sectioned at 5 µm. The amount of proteoglycans was 
evaluated by aqueous Safranin-O (0.1%) using standard procedures.  
For osteogenic differentiation, 1 x 104 hiPSC-derived MSCs were cultured for 3 
weeks in osteogenic media composed of DMEM, 10% FBS, 10% FBS, 100 U/ml 
penicillin-streptomycin, 100 nM dexamethasone, 10 mM β-glycerophosphate, and 0.1 
mg/mL ascorbic acid-2-phosphate (all from Sigma). To assess osteogenic potential 
(calcium deposition), cells were fixed with 10% formaldehyde, rinsed with distilled water, 
and stained with Alizarin red [Sigma; 0.5% (v/v) in distilled water (pH 4.2)] for 10 min. 




citrate-buffered acetone, and incubated in a mixture of fast violet B salt (Sigma) and 
naphthol AS-MX phosphate (3-(Phosphonooxy)-N-(2,4-xylyl)naphthalene-2-
carboxamide) solution (Sigma).  
Differentiation and characterization of osteoclastogenic monocytes/macrophages 
from hiPSCs  
Directed differentiation of hiPSC to monocytes/macrophages was carried out as 
previously described [18, 19]. Briefly, for EB formation, hiPSCs were detached from 
plate and feeder cells by treatment with 0.2% dispase for 4 min and were collected by 
scraping. The hiPSCs were transferred into 6-well, ultra-low-attachment plates (Costar) 
in EB culture medium and were cultured for 4 d at 37°C. For monocyte differentiation, 
4–10 large EBs were transferred into gelatin-coated six-well plates containing monocyte 
differentiation media comprised of DMEM, 10% FBS, 50 ng/mL human macrophage 
colony-stimulating factor (hM-CSF) (PeproTech), 25 ng/mL human IL-3 (PeproTech), 1 
mM L-glutamine, 1× NEAA, and 0.1 mM β-ME. Continuous monocyte production 
started within 15-20 d and monocytes were harvested every 4–5 d for 2 months [17].  
For macrophage differentiation, monocytes harvested from EB factories were 
resuspended in macrophage differentiation medium comprised of RPMI, 10% FBS, 100 
ng/mL hM-CSF, glutamine, and 100 U/ml penicillin-streptomycin and plated at a density 
of 3 - 5 × 104 cells in 24 well plates or CorningR osteo assay surface 96-well plates, 
changing the media once in two days. For osteoclast differentiation, after 3 days of 
seeding, we added 100 ng/ml recombinant human soluble RANK ligand in macrophage 




and CATK-positive osteoclastic cells. Resorbed calcium phosphate was visualized by 
Von Kossa staining after the removal of all cells on osteo assay surface 96-well plates. 
Briefly, the plates were stained with 5% silver nitrate solution under ultraviolet light for 
15 min, washed three times with distilled water, and incubated with 5% sodium 
thiosulfate for 5 min at room temperature under regular light to quench unreacted silver. 
Then images were acquired by using a light microscope. In addition, iPSC-osteoclasts 
were stained for cathepsin K using mouse anti-cathepsin K (Millipore) and for F-actin 
using Alexa fluor 568 phalloidin (Life technologies).  
Polymer scaffold preparation 
The HA composite scaffolds composed of a 1:1 ratio of poly(lactide-co-glycolide) 
(PLGA) (Sigma, Mw ≈ 30 kDa) and poly(L-lactic acid) (PLLA) (Sigma, Mw ≈ 55 kDa) 
were fabricated by salt-leaching method, as described previously [15]. Briefly, PLGA and 
PLLA (1:1) were dissolved in chloroform to yield a solution of 5% (w/v) polymer with or 
without HA particles (Sigma, 1% or 5% w/v). Sponges (1 x 1 x 0.5 cm3) were sterilized 
overnight in 75% (v/v) ethyl alcohol overnight, washed three times with PBS, and coated 
with fibronectin (10 ng/ml) for 3 h before cell seeding.  
Flow cytometry 
hiPSC-MSCs, -monocytes, and -macrophages were harvested and resuspended to 
3 x 105 cells in 50 µl of PBS containing 0.1% BSA. Cells were separately labeled with 
phycoerythrin (PE)-conjugated mouse anti-human antibody CD44 (Millipore), CD68 and 
CD73 (Pharmingen), FITC-conjugated mouse anti-human antibody CD105, CD45 




CD14 and CD68 (Pharmingen) on ice for 30 min. An isotype-matched mAb was used as 
a control (Becton Dickinson). Data were analyzed with the BD AccuriTM C6 flow 
cytometer and FlowJo X 10.0 software (Becton Dickinson). 
RNA extraction and real-time RT-PCR  
Total RNA was extracted from cells, micromass, and HA composite scaffolds 
using Trizol reagent (Life Technologies) and cDNA was synthesized by using 
Superscript(R) II reverse transcriptase following the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA). Real-time PCRs were performed using StepOnePlus(R) Real Time PCR 
System (Applied Biosystems, Carlsbad, CA) with SYBR Green PCR Master Mix (Life 
Technologies). The relative expression of each target was calculated using the ΔΔCT 
method and β-actin were used as endogenous references. All expression levels of samples 
were normalized to controls. The PCR primers used for RT-PCR are listed in Table 1. 
Expression of all markers was normalised to the expression of the housekeeping gene β -
actin. 
Osteocalcin and TRAP 5b ELISA assay  
The osteocalcin ELISA assay was performed with the MicroVue Osteocalcin EIA 
Kits (Cat 8002; Quidel) following the manufacturer’s instructions. The TRAP ELISA 
assay was performed with the BoneTRAP (TRACP 5b human) ELISA (Cat SB-TR201R; 
ids) following the manufacturer’s instructions. For assaying the osteocalcin and TRAP 
released from HA composite scaffolds, a serum-free medium was used 48 h before 
protein harvest. Optical density was measured at 405nm using the microplate reader 




using quadratic curve fit. 
In vivo subcutaneous transplantation  
hiPSC-derived MSCs were expanded (passage 4), seeded (1.5 x 106) onto the 
polymer sponges (1 x 1 x 0.5 cm3), and cultured under MSC growth medium for 1 day. 
After treatment with an osteogenic-supplement dexamethasone and β-glycerophosphate 
and 10 nM 1α,25 dihydroxyvitamin D3 (Sigma) for 7 days, hiPSC-MSC/scaffolds were 
seeded with hiPSC-macrophages (passage 0; 1.5 x 106) and incubated for 5 days without 
osteogenic-supplements but containing 50 ng/ml M-CSF followed by co-culture in the 
presence of 100 ng/ml RANKL and 100 ng/ml M-CSF for another 5 days. The cell-
seeded scaffolds were implanted subcutaneously into the dorsal region of 6-week-old 
athymic female nude mice (Charles River Laboratories; n = 18) and the skin was closed 
with a nylon suture. Constructs were harvested after 8 weeks and processed for histology. 
All procedures were performed under a pre-established protocol (The Johns Hopkins 
University Animal Care and Use Committee approved the animal procedures, protocol 
number MO14M126). 
Histological analysis of explanted scaffolds 
The tissue constructs were fixed in 10% formalin, embedded in optimum cutting 
temperature (OCT) compound (Tissue-Tek, Sakura Finetek), and cryosectioned (8 µm 
thick). The cryosections were immediately stained with hematoxylin and eosin, Masson’s 
Trichrome, Alizarin Red S, Von Kossa, or TRAP or stored at -80°C until use. Images of 




minimal intensity threshold was used to eliminate the background and then the stained 
Alizarin Red S and Von Kossa were measured as image % area coverage. 
For immunohistochemistry, the sections were blocked with 20% normal goat 
serum in 2% BSA for 30 min, and incubated with rabbit polyclonal antibodies against 
osteocalcin (Millipore) (1:100 dilution), type I collagen (Abcam) (1:100 dilution), and 
cathepsin K (Biovision) (15 µg/ml dilution) at 4°C overnight. The sections were then 
incubated with Alexa Fluor 594 goat anti-rabbit secondary antibody H+L (Life 
Technologies) (1:300 dilution) or FITC-conjugated affinipure goat anti-rabbit secondary 
antibody H+L (Jackson Immunoresearch) (1:50 dilution) for 1 h and counterstained with 
DAPI (Chemicon) for 10 min. Human-specific nuclei staining was also performed with 
mouse IgG1 human lamin A+C (Abcam) (1:100 dilution) and goat anti-mouse Alexa 
fluor 488 (Life technology) (1:400 dilution). All images were collected with a Zeiss LSM 
Metal Confocal microscope. The intensity of osteocalcin and type II collagen was 
quantified as the integrated density subtracted from the mean fluorescence of background 
using the ImageJ software (NIH). 
Statistical analysis 
All analyses were performed in triplicate samples for n = 3 at least. Real time RT-
PCR was also performed on triplicate samples (n = 3) with triplicate readings. Data are 
expressed as average +/- standard deviation and the statistical significance (P value) was 
determined by One-way analysis of variance (ANOVA) with the Turkey post hoc test 




2.3 Results  
Differentiation of osteoblasts and osteoclasts from hiPSCs 
hiPSCs cultured in suspension as EBs for 1 week differentiated into mesenchymal 
precursor cells after 10 days on gelatin-coated tissue culture plates. Cells that isolated 
from outgrowth of EBs and then expanded in monolayer culture with MSC growth 
medium exhibited typical fibroblastic cell morphology (Fig 2.3A), expression of MSC 
surface markers CD44, CD73, and CD105 (Fig 2.3B), and the potential to differentiate 
into three different cell linages: osteoblast (Fig 2.3C), chondrocyte (Fig 2.3D), and 
adipocyte (Fig 2.3E). Under osteogenic conditions, hiPSC-MSCs displayed bone-specific 
alkaline phosphatase (ALP), calcium deposition, and up-regulation of runt-related 
transcription factor 2 (RUNX2), type I and X collagen (COLI and COLX), and osteocalcin 
(OCN) genes during 14 days of monolayer culture (Fig 2.3C). hiPSC-MSCs grown for 28 
days in 3D micromass culture or monolayer culture under chondrogenic or adipogenic 
conditions, respectively, produced proteoglycans and accumulated lipid with up-
regulation of SOX-9 and Aggrecan (Fig 2.3D) as well as gene expression of fatty acid 
binding protein (FABP), lipoprotein lipase (LPL), and CCAAT-enhancer-binding proteins 
(C/EBP) (Fig 2.3E).  
To induce OC from hiPSCs, we used a stepwise mono-culture approach based on 
our previous derivation strategy [18] involving EB formation (Fig 2.4A, i), direct 
differentiation to monocytes (Fig 2.4A, ii and iii) and macrophages (Fig 2.4A, iv), and 
differentiation into OCs (Fig 2.4C). With this approach, hiPSCs cultured in suspension as 




17 days with monocyte differentiation medium. Monocyte surface marker CD14 was 
expressed in more than 80% of collected cells floating in the culture medium (Fig 2.4B). 
Monocytes were then differentiated into macrophages after plating onto adherent tissue 
culture plates for 5 days with macrophage differentiation medium supplemented with 
macrophage colony-stimulating factor (M-CSF) and IL-3. These cells had similar 
morphologies to spread-out macrophages (Fig 2.4C, iv) and expressed macrophage 
markers CD14, CD68, and CD115 (Fig 2.4B).  
Next, hiPSC-derived macrophages were cultured in the presence of RANKL and 
M-CSF, which are essential cytokines for osteoclast differentiation and survival. Fourteen 
days after RANKL stimulation, multinucleated (>3 nuclei) and tartrate-resistant acid 
phosphatase (TRAP)–positive OCs were observed, as well as resorptive pits left by OCs 
(Fig 2.4C). In hiPSC-derived OCs, cathepsin K colocalized with F-actin—a cysteine 
protease secreted by OCs during bone resorption and a characteristic feature of those 
cells to appose the bony surface for matrix digestion—, indicating functional OCs.  
Engineered 3D model of bone using both hiPSC-derived MSCs and macrophages  
We developed a two-step culture approach to provide hiPSC-MSCs with a 
scaffold on which to differentiate into OBs and deposit bone like-matrix; then, OCs could 
be activated and survived. The goal was to co-culture hiPSC-MSCs and -macrophages 
committed to OB and OC lineages, respectively, on a HA-based 3D porous polyester 
composite scaffold. We reasoned that such a co-culture would mimic the in vivo bone 
environment and allow for natural crosstalk between bone cells.  




monocyte differentiation into OC formation and their related function [20, 21]. Thus, we 
first focused on identifying an optimal culture regimen to ensure development of OC by 
inducing the differentiation of hiPSC-MSCs in medium with osteogenic supplements 
dexamethasone, β-glycerophosphate, and 1α,25-dihydroxyvitamin D3 followed by co-
culturing with hiPSC-macrophages either with (+) or without (-) osteogenic supplements 
in a monolayer. Co-culture without osteogenic supplements exhibited large 
multinucleated OCs with diameters of 50-100 µm embedded in OBs (Fig 2.5A) in 
contrast to co-culture with osteogenic supplements. In the absence of osteogenic 
supplements, there were significant increases in the expression of OC-related genes 
nuclear factor-activated T cells c1 (NFATC1), calcitonin receptor (CTR), and cathepsin K 
(CATK), as well as RANKL, which is expressed by OBs, compared to co-culture in 
osteogenic supplements (Fig 2.5B). OB-related gene expression of OCN was higher for 
both hiPSC-derived cultures under the osteogenic supplements, which showed a typical 
high value due to the addition of osteogenic supplements. As a reference, the expression 
levels of all OC-related markers were not detected in the hiPSC-MSC mono-culture with 
and without osteogenic supplements. Thus, OCs could be differentiated from hiPSC-
macrophages in osteogenic supplement–free medium when co-culturing with hiPSC-
derived OBs.  
The established monolayer co-culture method was then adapted for 3D tissue-
engineered model of bone to evaluate whether crosstalk between these cells improves 
bone formation over existing mono-culture approaches (Fig 2.5C). We first seeded 
hiPSC-MSCs onto the scaffolds with varying amounts of HA (HA-0, -1, and -5: 




and 5% w/v HA, respectively). The cells were allowed to attach on the surface of the 
scaffolds and adapt to the new environment under MSC growth medium supplemented 
with basic fibroblast growth factor (b-FGF) for 2 days. Subsequently, the hiPSC-MSC-
seeded scaffolds were differentiated into OBs by cultivation with osteogenic supplements 
for 7 days. The scaffold was then seeded with hiPSC-macrophages and incubated for an 
additional 5 days, without osteogenic supplements, but with M-CSF followed by RANKL 
and M-CSF for another 5 days. These cell-seeded scaffolds were either grown in vitro to 
develop bone tissue for analysis or implanted subcutaneously into athymic nude mice (an 
ectopic bone regeneration model).  
Adding hiPSC-macrophages to hiPSC-MSCs accelerates in vitro bone tissue 
formation  
In the engineered 3D constructs with only hiPSC-MSCs, after 28 days there was a 
noticeable increase in expression of OB-related genes, including RUNX2, COLI, ALP, 
OCN in HA-5 compared with no HA (Fig 2.6A). When hiPSC-MSCs were co-cultured 
with hiPSC-macrophages in HA-5, there was a shift in osteogenic gene expression: 
increases in expression of osteopontin (OPN) and release of OCN as later stage of 
osteogenic markers [22] (Fig 2.6A, B), with a concomitant decrease in early osteogenic 
markers COLI and ALP as well as RUNX2 transcriptional expression. Co-cultured cells 
on HA-5 composite scaffolds produced more maturation of bone-specific matrix and 
mineralization than HA-1 and HA-0 scaffolds (Fig 2.6C).  
In HA-5 3D composite scaffolds with co-culture, hiPSC-macrophages appeared 




CTR, and TRAP 5b (Fig 2.7A) and TRAP 5b enzyme activity than HA-0 and -1 
composite scaffolds (Fig 2.7B). TRAP-positive OCs were observed at the construct edges 
or scaffold surfaces in the HA-containing co-culture scaffolds (Fig 2.7C, red arrowhead). 
As a reference, the expression levels of all OC-specific markers and TRAP activity were 
not detected in the hiPSC-MSC mono-culture under the same conditions, indicating that 
OC differentiation did not occur. Overall, the accelerated tissue development in the HA-
based co-culture constructs suggests the important role of a dynamic interplay between 
OCs (TRAP activity) and OBs (OCN presence) in bone maturation.  
hiPSC-MSC/-macrophage co-culture induces mature bone-like tissue formation in 
vivo 
To determine whether hiPSC-MSCs co-cultured with hiPSC-macrophages within 
the 3D scaffold could maintain stable osteoblast and osteoclast lineage commitments and 
constitute functional bone tissues in vivo, we implanted constructs subcutaneously in 
athymic nude mice. Eight weeks after implantation, explanted scaffolds (lacking HA) 
from mono-cultured hiPSC-MSCs were filled with fibrous connective tissue, but did not 
have bone matrix deposition. However, hiPSC-MSCs on HA-5 composite scaffolds 
produced copious osseous tissue and high levels of OCN, COLI, and calcium deposition, 
resulting in faster bone formation than HA-0 and -1 composite scaffolds (Fig 2.8A). In 
agreement with our in vitro finding, the co-culture constructs formed more mature bone 
with lamellar structure (H&E), organized collagen fibers (Masson’s trichrome), more 
OCN and COLI production, and osteocytes embedded in mineralized extracellular matrix 
(Alizarin Red S and Von Kossa) in HA-5 composite scaffolds compared with the hiPSC-




formation further confirmed that hiPSC-MSC/-macrophage on HA-5 composite scaffolds 
formed large areas of mineralized bone in the form of calcium and phosphate deposits 
with concomitant increases in OCN and COLI production, compared with mono-cultured 
hiPSC-MSCs (Fig 2.8B). No evidence of teratoma around the site of implant was 
observed in any of the scaffolds at 8 weeks. We also confirmed the human origin of 
engineered bone tissues for all scaffolds by staining for human lamin A+C (Fig 2.9). 
We then analyzed functional behavior of OCs in the engineered bone constructs 
from hiPSC-MSC/-macrophage co-cultures in vivo. Histological examination revealed 
that TRAP-positive and CATK-expressing OCs in co-culture were more homogeneous 
and abundant, in a HA-dose dependent manner, compared with mono-cultured hiPSC-
MSCs (Fig 2.10). Mono-cultured hiPSC-MSCs showed similar, but much lower, 
production of the TRAP resorbing enzyme at the construct edges or surfaces of scaffolds 
than co-cultured hiPSC-MSC/-macrophage. These data point toward active bone 
resorption by osteoclastogenic hiPSC-macrophages in HA-containing scaffolds, as well 
as bone formation and functional maturation by hiPSC-derived OBs. 
Coordinated hiPSC-derived OB and OC activity leads to engineered bone-like 
tissues  
We next examined the molecular details of the pathways that accelerated bone-
like tissue formation in our HA scaffolds. OPG/RANKL are key molecular coordinators 
expressed by OBs that regulate bone resorptive activity of OCs and are responsible for 
the homeostatic mechanism of bone remodeling [23]. RANKL stimulates OC precursors 




precursor and mature OCs. OPG is a suppressor of osteoclastic bone degradation by 
competing with RANK for binding of RANKL. In the engineered constructs from hiPSC-
MSCs treated in vitro with osteogenic supplements for 28 days, the expression of OPG 
remained unchanged in varying HA concentrations while RANKL expression increased 
two fold in HA-5 composite scaffolds (Fig 2.11A). However, the constructs with hiPSC-
MSCs/-macrophages co-cultured showed a significant increase in both OPG and RANKL 
expression in HA-5 composite scaffolds. These data suggest that the high dose of HA 
prevents unintended, excessive hiPSC-macrophage osteoclastogenesis by increasing OPG 
production, which blocks the actions of RANKL in the co-culture. As a consequence, the 
ratio of OPG/RANKL, which determines the extent of OC activity [24], was close to 1 in 
HA-5 with hiPSC-MSC/-macrophage co-culture, further supporting balanced bone 
formation and resorption processes.  
  We also assessed several inflammatory molecules, expressed by OCs and their 
precursors, that bound directly to OB precursors to enhance the differentiation and 
function of OBs [25]. Co-culture systems with a higher percentage of HA resulted in a 
dose-dependent up-regulation of IL-6 and IL-1β expression with no significant change in 
TNFα in all scaffolds (Fig 2.11B). However, the expression of IL-6, IL-1β, and TNFα did 
not change markedly in all scaffolds when only hiPSC-MSCs were cultured under 
osteogenic conditions. Taken together, our findings suggest that co-cultured cells on the 
HA-based constructs induce coupling signals coordinating OB and OC activity, resulting 







The field of tissue engineering is increasingly focused on harnessing hiPSCs and 
their derivatives with the combined use of biomaterials to build or regrow patient-specific 
tissues, such as bone. hiPSCs developed from a patient’s own somatic cells have an 
indefinite potential to differentiate into all cell types residing in the human bone—
osteoblast, osteocyte, and immune cells, such as monocytes, macrophages, and 
osteoclasts [6, 13]. However, current bone tissue engineering approaches, which 
primarily rely on the cultivation of MSCs as bone-forming osteoblast precursors, do not 
produce functional bone substitutes in a way akin to the physiological bone regeneration 
process. In the body, bone cells (mainly osteoblasts and osteoclasts) coordinate and 
balance their respective anabolic and catabolic processes to maintain functional 
equilibrium during the extracellular matrix remodeling process [26]. Thus, an attempt to 
recreate the crosstalk between these two cell types, using hiPSCs and biomaterial 
platforms, could produce functional and sophisticated bone substitutes.  
Recent studies have similarly evaluated using hiPSCs for bone regeneration [7, 10, 
11, 27-29]. However, our data highlighted the need for bone extracellular matrix 
remodeling that is modulating through immune cells being required for maturation of 
bone by including hiPSC-derived OCs in addition to OBs. We hypothesized that the 
formation of new bone in vivo requires a balance between the anabolic activity of 
osteoblasts and the catabolic function of osteoclasts. We report a novel 3D human bone 
model that was engineered by co-culturing hiPSC-derived MSCs and macrophages on 




structure of native human bone [10]. In our in vitro study, the composite scaffolds with 
higher percentage of HA not only induce the osteoclastic differentiation of hiPSC-
Macrophage (by NFATC1, CATK, CTR, and TRAP5b) but also stronger osteogenic 
activity of hiPSC-MSCs compared to low HA or PLLA/PLGA alone. Notably, co-
cultured cells with HA-based composites showed the expression level of OCN and OPN 
increased while early osteogenic markers including COL1 and ALP decreased compared 
with mono-cultured hiPSC-MSC, indicating differentiation into mature OBs. Decreased 
RUNX2 observed in co-cultured hiPSC-MSC/-macrophage on high-HA composites could 
be due to the temporal changes in its mRNA expression during osteogenesis [30]. 
Our ectopic bone formation model demonstrated that unlike the composite scaffolds 
containing low HA or without HA, where fibrous connective tissues are found throughout 
the constructs, in high-concentration HA scaffolds co-cultured hiPSC-MSC/-macrophage 
formed mature bone with lamellar collagen fibers and increased nonmineralized (by OCN 
and COLI) and mineralized bone matrix deposition. The underlying mechanisms appear 
to involve the balanced OPG/RANKL ratio that mediate the coordinated activity between 
actions of bone-building osteoblasts and bone-resorbing osteoclasts critical for bone 
remodeling [23]. Like our previous study [15], this could be attributed that special 
biochemical and biophysical cues created by the addition of HA particles preferentially 
direct the differentiation of hiPSC-MSCs/-macrophages into OBs and OCs, thereby 
allowing for functional engraftment of hiPSC-derived cells into engineered bone tissues. 
Osteoblasts control the formation and activity of osteoclasts and, therefore, the 
resorption of bone through coupling mechanisms such as RANK, RANKL, and OPG [31, 




play a pivotal, non-immunological regulatory role in bone formation, regeneration, and 
homeostasis in vivo [25, 33]. Indeed, bone-specific macrophages named osteal 
macrophages have been identified recently in human bone and secrete inflammatory 
molecules to facilitate bone formation and remodeling [34, 35]. There are also clinical 
reports that the inhibition of OC-mediated bone resorption by bisphosphonate 
administration in patients with osteoporosis developed osteonecrosis of the jaw [36], 
implying an important role of immune cells in supporting the bone repair and 
regeneration process. It is clear from our in vitro and in vivo studies that macrophages 
and differentiated OCs in combination with OBs are necessary for engineering mature 
bone-like tissues.  
We also verified that bone-specific signaling pathways were reproduced in our 
engineered scaffold co-cultures. IL-6, for instance, is a potent cytokine secreted by 
osteoclasts and their precursors, which facilitates calvarial bone formation in mice [37], 
and IL-1β induces MSC differentiation into osteoblasts [38] and is required for tissue 
ingrowth and bone formation in rabbits [39]. TNFα plays an essential role in commitment 
to the osteoclastic lineage and activation of mature OCs by precisely tuning IL-6, 
RANKL, M-CSF, and OPG [40]. Here, we found that the induction of IL-6, IL-1β, and 
TNFα—expressed by hiPSC–derived OCs and their precursor macrophages in our HA-
based constructs—worked together to stimulate OB differentiation and bone formation, 
indicating the necessity of crosstalk between these bone cell types (Fig. 5C). Furthermore, 
promotion of RANKL production by OBs induced differentiation of hiPSC-macrophages 
into OCs. Interestingly, OPG synthesis was stimulated by cellular interaction with the HA 




Thus, the balance of bone formation versus resorption was improved by pairing co-
cultured cells with HA-based composites. These findings suggest that local cues provided 
by the HA niche can guide intercellular signaling between hiPSC-MSCs and -
macrophages to more accurately mimic bone physiology. Similar to wound healing [41], 
it is clear that cytokines and regulatory molecules secreted by immune cells 
(macrophages and OCs) can tightly regulate extracellular matrix remodeling required 
during development and maturation of bone.  
 
2.5 Conclusions 
3D bone tissue model engineered from hiPSCs not only elicited controlled differentiation 
of two bone cell precursors, but also demonstrated preliminarily functional regeneration 
of human bone-like tissue in vivo. Further investigation in orthotopic implantation models 
will be required to validate the functionality, especially for vascularization, which leads 
to better bone formation [42], and to confirm safety of bone grafts engineered from 
hiPSCs in the long run. From a translational standpoint, our 3D tissue-engineered bone 
using patient-specific iPSCs could capture the functional interplay between osteoclastic 
and osteoblastic activities and thus, it could be used in understanding of bone cell 








2.6 Figures  
 
Figure 2.1 Regeneration in human bone and bone tissue engineering. (A) Human 
bone regeneration is comprised of a complex series of bone formation along with 
remodeling of bone through heterotypic interactions between monocytes/macrophage and 
bone cells (osteoblast and osteoclast). (B) Current bone tissue engineering approach uses 
synergistic combinations of osteoprogenitors, scaffolds, and factors to produce bone 


















Figure 2.2 Human induced pluripotent stem cells (hiPSCs) for bone tissue 
engineering. hiPSCs are prospective cell sources for engineering bone because they have 
an unlimited potential to generate all cell types residing in human bone such as OB and 






Figure 2.3 Isolation and characterization of hiPSC derived-MSC. (A) Light 
microscopy of hiPSC-MSCs migrating out of the embryoid body (EBs) for a week (Left) 
were harvested and expanded in monolayer culture with MSC growth medium (Right). 
(B) Flow cytometry analysis of hiPSC-MSCs indicates that these cells express MSC 
surface markers (at passage 3). Histograms show the percentage of cells stained with 
antibodies to specific markers (Blue) and isotype controls (Grey). In vitro differentiation 
potential of hiPSC-MSCs towards: (C) an osteogenic lineage (ALP and Alizarin red 
staining and gene expression of RUNX2, COL I, COL X, and OCN after 7 and 14 days in 
monolayer cultures); (D) a chondrogenic lineage (proteoglycan production confirmed by 
Safranin-O staining and gene expression of SOX-9 and Aggrecan); and (E) an adipogenic 
lineage (Oil Red-O staining and gene expression of FABPs, LPL, and C/EBPα). Data in 





Figure 2.4 Isolation and characterization of hiPSC derived-macrophage and their 
potential of osteoclastogenesis. (A) A stepwise derivation strategy for differentiation of 
macrophage from hiPSCs. (i) Ten-day-old embryoid body (EBs) in suspension culture, 
(ii) flattened EBs that were ready to produce monocytes after 17 d with monocyte 
differentiation medium, (iii) EB factories producing monocytes (Floating round 
monocyte-like in the culture medium, arrow), and (iv) monocytes differentiated into 
macrophages after plating onto adherent tissue culture plates for 5 days with macrophage 
differentiation medium supplemented with M-CSF and IL-3. (B) Flow cytometry analysis 
of hiPSC-monocytes and macrophages. Histograms show the percentage of cells stained 
with antibodies to specific markers (Blue) and isotype controls (Grey). (C) 
Differentiation of osteoclast from hiPSCs shown by TRAP-positive osteoclastic cells 
(left), resorption pits created by functional hiPSC-derived OCs (arrow; Middle), and 





Figure 2.5 Engineered 3D model of bone using hiPSC-derived MSC and 
macrophage combination. (A) hiPSC-MSCs and -macrophages were co-cultured for 14 
days with (+) or without (-) osteogenic supplements. Light microscopy images show 
multinucleated OCs (circles) embedded in an osteoblastic cell layer (arrow). Scale bars, 
200 µm. (B) Gene expression for OC-expressing markers, NFATC1, CTR, and CATK 
(Right) and OB-expressing markers OCN and RANKL (Left) on day 14 of co-culturing 
hiPSC-MSCs and -macrophages in a monolayer with or without osteogenic supplements. 
Data are averages ± SD (n=3). *p < 0.05, **p < 0.01, for osteogenic supplements (-) vs. 
(+); $p < 0.05, $$$p < 0.001, for hiPSC-MSC/macrophage co-culture vs. hiPSC-MSC 
mono-culture. (C) Schema for protocol and timeline. hiPSC-MSCs were seeded and 
allowed to attach to the HA-based composite scaffolds in MSC growth medium for 1 day. 
Medium containing osteogenic supplements was used to commit these cells to the OB 
lineage for 7 days, after which it was seeded with hiPSC-macrophages and incubated 
without osteogenic supplements, containing M-CSF and RANKL, to differentiate into 
both OB and OC lineages for 10 days. hiPSC-derived multicellular bone constructs were 






Figure 2.6 hiPSC-macrophage addition to hiPSC-MSC culture accelerates in vitro 
bone tissue formation. Bone tissue development from hiPSC-MSCs was compared with 
hiPSC-MSCs/-macrophages on PLGA/PLLA scaffolds or HA composite PLGA/PLLA 
scaffolds for 3 weeks. (A) Quantitative real-time PCR of gene expression for osteogenic 
markers RUNX2, COLI, ALP, and OCN. (B) OCN released into culture medium, 
indicative of bone maturation. Data in (A and B) are averages ± SD (n=3). *p < 0.05, **p 
< 0.01, ***p < 0.001, as indicated; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. hiPSC-MSC 
in the same dose of HA. (C) Immunofluorescent staining for OCN and Alizarin S red 
staining of hiPSC-MSC and hiPSC-MSC/macrophage in the various concentrations of 
HA-based scaffolds. HA-0: PLGA/PLLA scaffold, HA-1: PLGA/PLLA scaffold with 1% 







Figure 2.7 hiPSC-macrophages differentiated into OCs in HA-based co-culture bone 
constructs in vitro. Osteoclastogenic potential of hiPSC-macrophages was characterized 
in vitro in hiPSC-MSC/-macrophage and hiPSC-MSC on PLGA/PLLA scaffolds or HA 
composite PLGA/PLLA scaffolds for 3 weeks. (A) Quantitative real-time PCR of gene 
expression for OC markers NFATC1, CATK, CTR, and TRAP5b. (B) TRAP5b released 
into culture medium, indicative of OC cell number. Data in (A and B) are averages ± SD 
(n=3). *p < 0.05, **p < 0.01, ***p < 0.001, as indicated; #p < 0.05, ##p < 0.01, and ###p < 
0.001 vs. hiPSC-MSC in the same HA dose. (C) Histological analysis of TRAP-positive 
OCs (red arrowhead) in hiPSC-MSC and hiPSC-MSC/macrophage in various HA-based 
scaffolds. HA-0: PLGA/PLLA scaffold, HA-1: PLGA/PLLA scaffold with 1% w/v HA; 





Figure 2.8 hiPSC-MSC/-macrophage co-culture induces mature bone-like tissue 
formation in vivo in mice. hiPSC-MSCs and hiPSC-MSC/-macrophages on 
PLGA/PLLA scaffolds or HA-composite PLGA/PLLA scaffolds were implanted 
subcutaneously for 8 weeks in the athymic nude mice. Histology revealed deposition of 
osseous tissue (H&E) and collagen (Masson’s Trichrome, blue), calcium accumulation 
(Alizarin red), and OCN expression. Bone resorptive activity of OCs was confirmed by 
TRAP and CATK staining. HA-0: PLGA/PLLA scaffold, HA-1: PLGA/PLLA scaffold 





Figure 2.9 Anti-human nuclei staining of Lamin A+C confirming human origin of 
3D engineered bone tissue. Human origin of the cells was confirmed by anti-human 
nuclei staining of Lamin A+C both in the engineered bone tissue for all hiPSC-MSC 
(Left) and hiPSC-MSC/-Macrophage groups (Right) investigated (Lamin A+C: green and 
DAPI: blue). HA-0: PLGA/PLLA scaffold, HA-1: PLGA/PLLA scaffold with 1% w/v 







Figure 2.10 Phenotypic and differentiation stability of hiPSC-macrophages to OCs 
in HA-based co-culture bone constructs in vivo. Bone resorptive activity of OCs 
differentiated from hiPSC-macrophages was confirmed by TRAP and CATK staining of 
the implanted scaffolds after 8 weeks. HA-0: PLGA/PLLA scaffold, HA-1: PLGA/PLLA 








Figure 2.11 Well-orchestrated coupling of hiPSC-derived OBs and OCs leads to 
bone-like engineered tissues. Bone tissue was created from hiPSC-MSC and hiPSC-
MSC/-macrophage on PLGA/PLLA scaffolds or HA composite PLGA/PLLA scaffolds 
for 3 weeks. (A) Expression of coupled factors OPG and RANKL, and their ratio. (B) 
Expression of cytokines IL-6, IL-1β, and TNFα. Quantitative real-time PCR data in (A 
and B) are averages ± SD (n=3). *p < 0.05, **p < 0.01, as indicated; #p < 0.05, ##p < 0.01, 
and ###p < 0.001 vs. hiPSC-MSC in the same HA dose. (C) Schematic for possible 
coupling mechanisms among hiPSC-derived OBs, OCs, and their progenitors under 
interaction with HA microenvironment for bone tissue development. HA-0: PLGA/PLLA 
scaffold, HA-1: PLGA/PLLA scaffold with 1% w/v HA; HA-5: PLGA/PLLA scaffold 
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Chapter 3. A potent sugar-based disease modifying 





Osteoarthritis (OA) is the most common cause of joint pain and physical disability in 
the elderly. The characteristics of OA include an irreversible loss of articular cartilage, 
subchondral bone thickening, osteophyte formation, and local joint inflammation[1] (Fig 
3.1). Current pharmacologic OA treatments are the use of analgesics, non-steroidal anti-
inflammatory drugs (NSAIDs), and viscosupplementation (e.g. hyaluronic acid) with 
intra-articular injections (Fig 3.2). These treatments focus on short-term symptomatic 
pain relief and care of joint function. With advances in the understanding of the OA 
pathogenesis, a variety of disease-modifying OA drugs (DMOADs) have been developed 
to block or reverse OA progressions, which target specific OA pathophysiological 
networks[2]. In spite of these successes, there still remains an unmet need for a desirable 
pharmacologic OA therapy. 
Recent pharmacological discoveries have been catalyzed by the recognition of OA as 
a whole joint disease [3]. The pathological changes of OA result from an imbalance in the 
dynamic equilibrium between the breakdown and repair of all the joint tissues including 




number of anabolic and catabolic factors in autocrine and paracrine manners [5]. These 
factors also participate in cross-talks and feedbacks between the joint tissues in order to 
regulate their expression. Due to this complex interrelationship, a single pharmacologic 
approach of DMOADs would provide limited therapeutic efficacy on OA. In fact, the 
most effective DMOADs in development have an action on OA through a combination of 
several therapeutic targets. For example, strontium ranelate exhibited OA structure-
modifying activity via modulation of bone turnover and anabolic effects on chondrocytes. 
Calcitonin has been shown to have beneficial metabolic effects on both bone and 
cartilage, promoting the growth of cartilage tissues. Bone morphogenetic protein 7 
(BMP-7) showed strong anabolic and anti-catabolic activities on cartilage matrix, 
inhibiting OA progression[6]. Therefore, a comprehensive approach to target multiple 
elements would be desirable in the development of new DMOADs[7]. 
Recently, as a new class of DMOADs, small molecules that stimulate MSCs residing 
in articular cartilages into chondrocytes have shown great promise as novel therapeutics 
for cartilage repair[8-10]. However, inflammatory cytokines present in an OA joint can 
disrupt chondrogenic differentiation capabilities of the MSCs and reduce therapeutic 
efficacy of the DMOADs[11]. These inflammatory mediators continuously can create 
positive feedback loop of the inflammatory pathways and further disturb the regeneration 
capability[12]. Modulating the inflammation in an OA joint thus would be necessary to 
create optimal conditions for the drug action along with advantageous anti-catabolic 
effects[13]. In this work, we investigated the use of a sugar-based compound, a 
tributanoylated N-acetyl-D-galactosamine (GalNAc-a) as a potential OA drug. Treatment 





Consequently, it improved cartilage tissue production on three-dimensional (3D) in vitro 
cultures. We further investigated the therapeutic efficacy of GalNAc-a an in vivo OA rat 
model. Intra-articularly injected GalNAc-a improved cartilage repair in the damaged 
joints. Additionally, its incorporation into a sustained-release drug delivery system could 
avoid multiple GalNAc-a injections, facilitating clinical translation. These results show 
that GalNAc-a has dual benefits for both endogenous MSCs and diseased OA 
chondrocytes, demonstrating its potential as a disease modifying OA drug.’ 
 
3.2 Materials and Method 
 
Cell isolation and culture 
Human articular cartilage samples explanted from OA patients undergoing total 
knee arthroplasty were received from the National Disease Resource Institution 
(Philadelphia, PA, USA) according to an IRB-approved protocol. The cartilage tissue was 
cut into 1 mm3 pieces, washed 3 times with phosphate-buffered saline (PBS) 
supplemented with 1% (v/v) penicilline streptomycin (Pen/Strep) solution, and digested 
on an orbital shaker for 16 h at 37 ◦C with 0.17% (w/v) type II collagenase (Worthington 
Biochemical, Lakewood, NJ, USA) in high-glucose Dulbecco’s modified Eagle’s 
medium (DMEM; In-vitrogenTM, Life Technologies) with 10% fetal bovine serum (FBS, 




strainer and cells were rinsed 3 times with the DMEM supplemented with 1% Pen/Strep 
and 10 % FBS.  
Human MSCs (hMSCs) were obtained from the Arnold Caplan’s lab, Case Western 
Reserve University, hMSCs were maintained in MSC medium with FBS from a lot 
defined by the Caplan Lab as supporting MSC growth. The human MSCs were 
maintained in growth medium composed of low-glucose DMEM supplemented with 1% 
l-glutamine, 1% Pen/Strep, 10% defined FBS, and 1ng/mL basic fibroblast growth factor 
(bFGF; PeproTech). Passage 3–5 cells were used for all experiments. 
Mesenchymal stem cell differentiation 
For chondrogenic differentiation (monolayer, pellet, and 3D hydrogel cultures), 
hMSC were induced in chondrogenic medium consisting of high-glucose DMEM, 1% 
Pen/Strep, 1% ITS premix (BD Bioscience, San Jose, CA, USA), 100 mM sodium 
pyruvate (Life Technologies), 40 mg/ml L-proline (Sigma-Aldrich), 50 mM ascorbic 
acid-2-phosphate, and 10ng/mL of transforming growth factor-β1 (TGFβ1). For 
osteogenic differentiation in monolayer cell culture studies, hMSCs were plated and 
cultured in the growth medium until they were confluent. Differentiation toward an 
osteogenic phenotype was then achieved through culture in osteogenic medium 
comprised of high-glucose DMEM supplemented with 10% FBS, 1% Pen/Strep, 100 nM 
de -glycerophosphate, and 0.1 mg/mL ascorbic acid-2-phosphate. 
Cell viability test with Alamar Blue assay 
 For measuring cell viability, hMSCs or hOA chondrocytes were plated in 96 well 




then medium was changed to chondrogenic or osteogenic medium containing 100 uM of 
GalNAc-a and cultured for an additional 3 days. The medium was aspirated from each 
well and the wells were washed 3 times with PBS. 100 ul of Alamar blue working 
solution (10% (v/v) Alamar blue in medium) was added to each well and the cells were 
further incubated for 4 h in an incubator at 37 °C.  The cell viability was then determined 
by measuring the fluorescence intensity at 570 nm. The result was shown as a percentage 
over the control (no GalNAc-a treatment).  
3D Pellet culture of hMSC 
 For hMSC pellets cultures, 400,000 cells were seeded in the 96 well MicroWell™ 
round bottom plate (Thermo Fisher Scientific) and the pellets were formed in the bottom 
by centrifuging at 150g for 10 min. The pellets were maintained at 37 °C with 5% CO2 in 
200 ul of the chondrogenic medium and were harvested after 21 days for analysis. The 
media were changed 3 times a week until the end of the experiment.  
3D hydrogel cell cultures 
For the 3D hydrogel culture, hMSC or human osteoarthritic chondrocytes (2 
million cells) were suspended in 100 uL of the poly(ethylene glycol)-diacrylate (PEGDA; 
SunBio, Seoul, Korea) precursor solution and the cell suspension transferred into sterile 
cylindrical molds. The PEGDA precursor solution was prepared by dissolving 100 mg of 
PEGDA in 1 mL sterile PBS and 5 uL of the photoinitiator (Irgacure 2959) in 70 % 
ethanol to create a final concentration of 0.05% (w/v) in the solution. Polymer cross-
linking was initiated by exposing UV light at 3 mW/cm2 with a wavelength of 365 nm 




cultured in a 1 mL of either chondrogenic or osteogenic medium with or without 100 uM 
of GalNAC-a. For human chondrocyte experiments, the medium was supplemented with 
10 ng/ mL of IL- tain OA pathophysiological condition. The media were 
changed 3 times a week until the end of the experiment. 
Biochemical analysis for GAG contents  
  The hydrogel constructs or pellets (n = 3 per group) were lyophilized for 2 days 
and then digested overnight in 125 mg/ml papainase (Worthington Biochemical Corp.) 
for 16 h at 60°C. The sulfated glycosaminoglycan (sGAG) content was determined by 
1,9-dimethylmethylene blue (DMMB) dye assay with measuring the absorbance at 525 
nm and using chondroitin sulfate as a standard. The DNA content was determined by 
using Hoescht Dye 33342 DNA assay and calf thymus DNA as a standard.1 The GAG 
content levels were expressed as micrograms of GAG per microgram of DNA for each 
construct. 
Alkaline phosphatase (ALP), Alizarin red and oil red O staining 
  For calcium deposition staining, cells were fixed with 10% formaldehyde for 15 
min at room temperature and rinsed 3 times with an excess of distilled water. The cells 
were then stained with alizarin red (Sigma; 0.5% (v/v) in distill water (pH 4.2)) for 10 
min at room temperature. For oil red O staining, after fixation of cells with 10% 
formaldehyde, lipid droplets were stained with 30 mg/ml oil red O (Sigma-Aldrich) in 
60% isopropanol. For alkaline phosphatase (ALP) staining, cells were rinsed with 




The cells were washed 3 times with distilled water and then incubated in a mixture of fast 
violet B salt and naphthol AS-MX phosphate solution in the dark for 45 min. 
RNA Isolation and Real-Time PCR 
  Total RNA was extracted from cells, hydrogels, and pellets using Trizol reagent 
(Life Technologies, Grand Island, NY) and cDNA was synthesized by using 
Superscript(R) II reverse transcriptase following the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA). Real-time PCRs were performed using StepOnePlus(R) Real Time PCR 
System (Applied Biosystems, Carlsbad, CA) with SYBRW Green PCR Master Mix (Life 
Technologies). The relative expression of each target was calculated using the ΔΔCT 
-actin and GAPDH were used as endogenous references. All expression 
levels of samples were normalized to controls. The PCR primers are listed as followings: 
Table 1. 
Western blot analysis 
  To assay the β-catenin protein, cells were harvested, washed twice with ice-cold 
PBS, and lysed with NE-PERTM nuclear and cytoplasmic extraction reagents (Thermo 
Scientific, USA) containing protease inhibitor mixture (Sigma, USA) according to the 
manufacturer’s instructions. Concentration of collected cytoplasmic and nuclear proteins 
was determined using the BCA assay (Pierce, USA). Protein were separated by 10% 
SDS-PAGE and then transferred onto polyvinylidene difluoride (PVDF) membranes. The 
membranes were blocked for two hours with 5% nonfat powdered milk in Tris-buffered 
saline containing 0.1% tween-20 (TBST) and incubated overnight at 4°C with primary 




USA), and β-tubulin (1:1000, Cell signaling, USA). After washing away unbound 
primary antibodies, the membranes were incubated with horseradish peroxidase-
conjugated secondary antibodies (1:5000, Bio-Rad, USA) and proteins were detected by 
chemiluminescence (Thermo scientific, USA). β-actin and β-tubulin were used as the 
internal control for the cytoplasmic and nuclear proteins, individually. 
Histology and immunohistochemistry of pellets and hydrogel 
  The pellets and hydrogel constructs were fixed in 4% paraformaldehyde overnight, 
dehydrated in increasing concentrations of ethanol, and embedded with paraffin. Five 
micrometer-thick sections were cut from the paraffin block and collected onto the glass 
slides. The sections were stained for proteoglycans with aqueous Safranin-O (0.1%) for 5 
mins, and then the specimens were mounted. For immunohistochemical staining, 
endogenous peroxidase of the sections was quenched using 2.5% (v/v) hydrogen peroxide 
in methanol and then incubated at 37°C with 0.25% (w/v) hyaluronidase for 1 h. AEC 
Broad Spectrum Histostain-SP Kit (Invitrogen, USA) was used following the 
manufacturer’s instructions. Primary antibodies for type I, type II, and type X collagen 
(Abcam, USA) using a 1:100, 1:300, and 1:50 dilution factor in 4% BSA dissolved in 
PBS.  
Immunocytochemistry 
  Monolayer cultures of human MSCs and chondrocytes were fixed in 4% 
paraformaldehyde, permeabilized with PBS containing 0.25% Triton X-100 for 10 mins, 
and then blocked with 4% bovine serum albumin (BSA) containing 0.25% Triton X-100 




catenin (1:100, Cell signaling, USA) overnight at 4°C. The cells were rinsed 3 times with 
PBS and incubated was goat anti-rabbit IgG (H & L) conjugated with Alexa Fluor 594 
(1:1000, Life technologies, USA). After washing, the nuclei were counterstained with 
DAPI for 5 mins. The expression of β-catenin in MSCs and chondrocytes were imaged 
by fluorescence microscopy (Carl Zeiss, USA).  
Preparation of PLGA-GalNAc-a microspheres and in vitro release 
  The GalNAc-a encapsulated PLGA microspheres (PLGA-GalNAc-a) were 
prepared by the solvent evaporation method. 150 mg of PLGA (poly (lactic-co-glycolic 
acid), acid terminated, lactide:glycolide 75:25, Mw 4,000-15,000, Sigma-Aldrich) 
polymer and 20 mg of GalNAc-a was in 2 ml of methylene chloride. The solution was 
slowly added into 50 mL of a 1% PVA (poly(vinyl alcohol), Mw ~25,000, Polyscience, 
Inc.) solution and stirred at 1000 rpm for 5 min. The mixture was then poured into 100ml 
of 0.5% PVA and stirring at ~ 700 rpm for 2 h at room temperature. The PLGA-GalNAc-
a microsphere were washed 5 times with distilled water and recovered by centrifugation. 
After re-suspension, the microspheres were freeze-dried and stored in - 20 °C before 
experiment. Particle size distribution of the microspheres was determined using a 
Zetasizer Nano ZS (Malvern, USA) and their morphologies were characterized by using 
scanning electron microscopy with an electron voltage of 5 kV. To determine in vitro 
release of GalNAc-a from the microspheres, 15 mg of PLGA-GalNAc-a (loading 1.5 mg 
of GalNAc-a) microspheres were suspended in 1 mL of PBS and incubated in a shaker 
bath at 37 °C. The microspheres were settled down by centrifugation and the amount of 
GalNAc-a released was calculated from the UV absorption measurements of the 




shaker bath at 37 °C for next measurements. After 32 days, the release profile showed a 
plateau region, indicating around 10% loading efficacy.   
Surgically induced OA rat model 
Six-week old male Sprague-Dawley rats (Charles River, Germantown, MD) 
weighing approximately 240g were used in the work. Rats were anesthetized with 3–5% 
isoflurane, and the skin over the medial aspect of the right femoro-tibial joint was shaved. 
The knee joint was exposed by a 1 cm longitudinal incision of skin and then joint capsule 
opened with a #10 scalpel. The medial meniscus was fully transected and reflected the 
meniscus toward the femur. The joint capsule overlying muscle and then skin were closed 
with 4 Vicryl suture. All procedures were performed according to the Institutional 
Animal Care and Use Committee at Johns Hopkins University School of Medicine.  
After the OA surgery, the rats of the multi-Gal group were given IA injections 
with 500 μg of GalNAc-a in 100 ul of vehicle (5 % DMSO in PBS) on days 7, 14 and 21. 
The rats of the single-Gal group were given IA injections with 100 μM of GalNAc-a in 
100 ul of the vehicle once on days 7. The rats of the PLGA-GalNac-a group were given 
IA injections with 15 mg of PLGA-GalNAc-a (loading 1.5 mg of GalNAc-a) in the PBS 
once on days 7. On day 28, the rats were sacrificed and the cartilage was collected for 
histological assessment of the medial tibial plateau joint through blinded graded 
observations by 2 observers, according to the Osteoarthritis Research Society 





  Data are expressed as mean standard deviation and the statistical significance (p 
value) was determined by an unpaired t test or one-way analysis of variance (ANOVA). 
The statistical significance was determined at p < 0.05. 
3.3 Results  
Enhanced chondrogenic differentiation of human MSC upon GalNAc-a treatment 
The sugar analog compound, GalNAc-a (Fig 3.3A) was synthesized and 
characterized as previously reported[14]. The promoting chondrogenic effect of GalNAc-
a on human MSCs (hMSCs) was initially evaluated in monolayer culture over 48 h under 
chondrogenic condition. Real time-PCR (RT-PCR) with mRNA isolated from the cells 
confirmed the increased expression of genes associated with chondrogenic markers 
including Sox9 and aggrecan (Fig 3.3B). We then investigated the involvement of Wnt 
-catenin signaling pathway influences 
chondrogenic differentiation of MSC[15] -catenin, the signal 
transducer to regulate the transcription of Wnt target genes, was determined by western 
blot analysis (Fig 3.3D) -catenin levels decreased in both nuclear and cytoplasmic 
compartments when treated by GalNAc-a. This finding was further confirmed by 
immunoflu -catenin (Fig 3.3E). RT-PCR analysis showed that treatment of 
GalNAc-a down- -catenin and Wnt target gene, axin2 
(Fig 3.3C). 
Next, we evaluated the chondrogenesis promoting effect of GalNAc-a on 3D 
pellet cultures of hMSCs. Upon treatment of GalNAc-a for 3 weeks, RT-PCR analysis 




associated with chondrogenic differentiation, including Sox9, type II collagen, and 
aggrecan (Fig 3.4A). Biochemical analysis of the pellets demonstrated that the amount of 
glycosaminoglycans (sGAG) per DNA content significantly increased while DNA levels 
had no significant difference (Fig 3.4B, C). The increased proteoglycan deposition 
further confirmed via histological staining using Safranin-O (Fig 3.4D). In addition, 
immunohistochemical staining of pellets revealed up-regulation of type II collagen but 
down-regulation of hypertrophic chondrocyte specific marker, type X collagen and the 
osteogenic marker, type I collagen, indicating retention of the cartilage phenotype.   
We also sought to evaluate the effects of GalNAc-a on the chondrogenic 
differentiation of hMSCs in a 3D hydrogel culture that mimics the cartilage environment 
and supports chondrogenesis[16]. RT-PCR results indicated significant up-regulation of 
the gene expression for chondrogenic markers, Sox9, aggrecan, and type II collagen (Fig 
3.5A). The GalNAc-a exposure increased GAG content in the 3D hydrogel constructs 
(Fig 3.5B, C). and increased extracellular matrix (ECM) accumulation was confirmed via 
Safranin-O staining for proteoglycans and immunohistochemistry for type II collagen 
(Fig 3.5D, E). 
Adverse effect of GalNAc-a on osteogenesis of hMSC 
Wnt/β-catenin signaling also has a critical role in bone development and 
homeostasis[17] -catenin impairs osteogenesis of 
MSC in vitro[18, 19]. To further examine the role of GalNAc- -
catenin signaling, the effect of GalNAc-a on osteogenic differentiation was investigated 




osteogenic marker, alkaline phosphatase (ALP) activity was attenuated upon treatment of 
GalNAc-a, confirmed by ALP staining (Fig 3.6A). This inhibitory effect of GalNAc-a 
was also reflected in the down- -catenin, the osteogenic 
transcriptional factor, Runx2, and Wnt transcription cofactor, LEF-1 (Fig 3.6B).  
After 10 days osteogenic induction, alizarin red staining for calcium deposition 
also exhibited a decreased mineralization in the GalNAc-a group (Fig 3.6C). RT-PCR 
results further confirmed that the gene expression for type X collagen and bone matrix 
markers, osteocalcin (OCN) and osteopontin (OPN) was significantly reduced (Fig 3.6D). 
However, at this point, gene expression of Runx2 showed basal level (Fig 3.7A). At 15 
days of osteogenic induction, the calcium deposition and gene expression of Runx2, OCN, 
and OPN showed no significant difference between control and GalNAc-a treatment 
groups (Fig 3.7B, C). Interestingly, hMSC treated with GalNAc-a exhibited lipid droplet 
accumulations, which were visualized by oil red O staining (Fig 3.6E). The intracellular 
lipid accumulation is commonly observed in adipocyte cells and adipogenic lineage of 
MSC[20]. RT-PCR further confirmed up-regulation of several adipogenic-related 
markers, fatty-acid-binding proteins (FABPs), lipoprotein lipase (LPL), and 
CCAAT/enhancer-binding protein alpha (CEBPA) (Fig 3.6F).  
Similar to what was shown in the monolayer culture, the adverse effect of 
GalNAc-a on osteogenesis of hMSC was also observed in a 3D hydrogel system. hMSCs 
encapsulated in the hydrogels were cultured in osteogenic medium containing GalNAc-a 
for 3 weeks. The histological analysis of the constructs showed that GalNAc-a treatment 




confirmed significant down-regulation of the gene expression for osteogenic markers, 
Runx2, OCN, and type I collagen (Fig 3.6H). 
Anti-inflammatory effect of GalNAc-a on human OA chondrocytes 
Next, we investigated the anti-inflammatory effects of GalNAc-a on human 
diseased articular chondrocytes. Primary human articular chondrocytes isolated from OA 
patients undergoing total knee arthroplasty were grown in the presence of IL-
maintain OA pathophysiological condition [21]. We examined mRNA expression of 
-
- -inflammatory cytokine expression. 
Treatment of GalNAc-a on the human OA chondrocytes for 48 h in monolayer culture 
significantly reduced gene expression of the inflammatory targets which are involved in 
OA (Fig 3.7A). 
This anti-inflammatory effect of GalNAc-a via modul
also observed in our previous report [22]. Because pro-inflammatory cytokine-induced 
-catenin signaling pathway [23, 
24], we next evaluated the involvement of Wnt genes and proteins. Western blotting 
-
catenin was decreased in both nuclear and cytoplasmic compartments by GalNAc-a 
treatment (Fig 3.7C, D). RT-PCR showed that treatment of GalNAc-a down-regulated 
-catenin, LEF-1, TCF-1, axin2, and c-jun (Fig 3.7B). 
We further evaluated the inhibitory effects of GalNAc-a on the human OA 




articular cartilage environments, and maintains chondrocyte phenotype better than 
monolayer cultures [16]. The human OA chondrocytes in the hydrogel were treated with 
GalNAc-a for 21 days in the presence of IL- -PCR results confirmed down-
- -degrading enzyme, MMP13 
(Fig 3.8A). The anti- -catenin 
signaling has been shown to have anti-catabolic effects on cartilage[25]. We further 
confirmed up-regulated gene expression for aggrecan and type II collagen, indicting its 
anabolic effect (Fig 3.8B). Additionally, the GalNAc-a exposure increased GAG content 
and ECM accumulation in the 3D hydrogel constructs, confirmed by biochchemical 
analysis (Fig 3.8C, D) and immunohisto- and Safranin-O staining (Fig 3.8E, F).  
Cartilage repair of OA induced rats by intra-articular injection of GalNAc-a  
Given that GalNAc-a showed both chondrogenic and chondroprotective effects on 
endogenous MSC and OA chondrocytes respectively, we investigated the efficacy of 
GalNAc-a in vivo via the medial meniscal transection (MMT) model of OA in the rat  [26]. 
After MMT was performed, GalNAc-
through the knee joint weekly (days 7, 14, and 21). There were no obvious post-surgical 
complications and systemic effects of GalNAc-a treatment (weight loss or significant 
swelling). At 5 weeks after the surgery induction of OA, the rats were sacrificed and 
histological assessments according to Safranin-O staining were carried out on the medial 
tibial plateau where the majority of the lesions were located on (Fig 3.9A). Grading of 
the histological assessments based on OARSI score exhibited the score of the multi-
GalNAc-a treated rats showed a 74% reduction as compared to that of the vehicle-treated 




The local intra-articular (IA) injection of therapeutics is feasible for OA treatment 
but rapid clearance of the IA injected drugs in the joint would limit their prolonged 
residence time from the target tissues [27]. Therefore, we evaluated sustained-release 
drug delivery of GalNAc-a by using PLGA (poly(lactic-co-glycolic acid)) microspheres 
that can maintain optimal systemic concentration of drugs for months in the joint  [28]. 
We fabricated PLGA-GalNAc-a microspheres (size of diameter: 3.8 ± 0.4 um) and 
showed sustained in vitro release profiles of GalNAc-a from PLGA-GalNAc-a 
microspheres for over a month (Fig 3.9B, C) The PLGA-GalNAc-a was intra-articularly 
injected one week after surgical induction of OA. Controls consisted of a single GalNAc-
a injection- and PLGA microsphere only-treated rats. The OARSI score showed 
improved cartilage repair in the PLGA-GalNAc-a treatment group, which is comparable 
to the multiple GalNAc-a treatment group (Fig 3.9D). 
 
3.4 Discussion 
OA is a chronic joint disease with accompanying cartilage degradation leading to 
persistent pain and limited mobility. This progressive and irreversible cartilage 
destruction is a hallmark in the development of OA. It results from imbalances between 
the production and breakdown of the joint tissues, associated with a number of anabolic 
and catabolic factors [29]. In a joint tissue, MSCs and chondrocytes play a key role in the 
articular cartilage regeneration. Chondrocytes located in articular cartilage produce both 
the extracellular matrix components and the enzymes to degrade aging ECM, maintaining 
homeostasis of the cartilage. In the OA state, the homeostatic balance is disturbed by 




mitotic activity of the chondrocytes and avascularity of cartilage tissue, the articular 
cartilage lacks innate ability to self-healing after the onset of OA [30]. 
MSCs are multipotent stem cells with the capability to self-renew and differentiate 
into multiple cell lineages, including chondrocytes, osteoblasts, and adipocytes. Recently, 
MSC-like cells have been identified in adult cartilage and they are also known to 
contribute to the maintenance of the cartilage homeostasis [31]. MSCs have received 
considerable attention for their potential use in cell-based therapies for OA treatment [32]. 
For example, microfracturing on subchondral bone utilizes and stimulates resident MSCs 
in bone marrow to repair cartilage damage. Additionally, local delivery of ex vivo 
cultured MSCs have shown promising outcomes in OA, likely as a result of the paracrine 
or immunomodulatory effects of the MSCs.  
Regulating cell fate, state, and function of MSCs by small molecules provides a 
new tool for stem cell-based therapies [33]. Recent efforts involving small molecule 
stimulation of latent articular cartilage MSCs to form chondrogenic nodules has shown 
great potential as a novel therapeutic strategy to repair diseased cartilage. In this work, 
we investigated GalNAc-a as a potential small molecule inducer of chondrogenic 
differentiation of human MSCs. Gene expression studies confirmed the enhanced 
chondrogenic effect of GalNAc-a (Fig 3.3B) -catenin 
signaling pathway is involved in the regulation of MSC differentiation into cartilage. The 
-catenin pathway is one of the fundamental mechanisms for cell fate, proliferation, 
and differentiation in embryonic development and tissue homeostasis [34]. So, we further 
investigated the involvement of Wnt genes and proteins upon GalNAc-a exposure and 




et al. foun -catenin during the developmental process caused an 
enhanced chondrocytes differentiation. Similarly, others have shown that inhibiting Wnt 
signaling in MSCs resulted in promoting chondrogenesis [35, 36]. In line with previous 
findings, our results suggest that GalNAc-a promoted chondrogenesis of hMSC by 
-catenin signaling activity. The cartilage tissue production 
associated with the stimulating chondrogenic effect was further examined on 3D 
hydrogel and pellet culture systems [37]. We observed recapitulation of the chondrogenic 
effect in the 3D cell culture environment, which confirmed the anabolic of GalNAc-a. 
Additionally, immunohistochemical staining of pellets treated with GalNAc-a exhibited 
down-regulation of hypertrophic chondrocyte specific proteins (Fig 3.4D), indicating 
retention of cartilage phenotype [38].  
The molecular mechanisms underlying chondrocyte hypertrophy is linked with 
activation of the Wnt signaling [38]. This motivated us to further investigate an effect of 
GalNAc-a on hMSC under osteogenic condition. It was reported that disruption of the 
Wnt signaling pathways improves chondrogenesis of MSC while impairing the 
osteogenic differentiating capacity of MSC [37]. Both gene expression and histological 
studies confirmed the observation of the adverse effect of GalNAc-a on the osteogenic 
differentiation of the hMSC. Interestingly, adipocyte features were observed after 15 days 
of osteogenic induction supplemented with GalNAc-a. The inverse relationship between 
osteogenic and adipogenic differentiation has been reported both in vitro and in vivo. 
Multiple signaling pathways are committed to the preferential induction of one lineage at 
the expense of the other. Particularly, inhibition of Wnt signaling promotes adipogenesis 




a on the Wnt pathway, it is suggested that our observation to the adipocytic phenotype 
presumably occurred at the expense of the reduced osteogenic differentiation by 
disruption of Wnt signaling activity. This adverse effect on the osteogenic differentiation 
concomitantly supports the results of the promoting effect of GalNAc-a on chondrogenic 
commitment of MSCs by modulation of Wnt signaling. 
The stimulation of endogenous MSCs into the chondrogenic lineage by small 
molecules has shown great promise as a novel cartilage-regeneration strategy. However, 
chronic inflammatory conditions in an OA joint may provide a sub-optimal environment 
for the small molecules to function. A large number of inflammatory cytokines present in 
an OA joint that disrupt regeneration capacity of the MSC could also limit the therapeutic 
potential of the small molecules. Modulating the inflammation could create favorable 
condition for the drug action on the endogenous MSCs. Moreover, inhibiting the 
inflammation has another benefit on cartilage homeostasis, which has been a primary 
therapeutic approach to the development of DMOADs. The inflammatory process 
secretes a variety of pro-inflammatory cytokines and inflammatory mediators, creating 
the catabolic state in autocrine and paracrine manner in the OA joint [12]. Therefore, 
anti-inflammatory drugs directed at the cytokines or inflammatory pathways could restore 
the cartilage homeostasis, delaying and reversing the progression of OA. 
Chondrocytes in the OA joint are one of the primary sources of inflammatory 
cytokines and mediators [40]. In the present study, we demonstrated that GalNAc-a 
exposure to the human osteoarthritic chondrocytes under OA pathophysiological 
conditions exhibited significant down-regulated gene expression of the inflammatory 




signaling in osteoarthritic chondrocytes is more activated than normal chondrocytes and 
linked with inflammatory cytokine-induced cartilage degradation in OA [41]. In line with 
the findings, Landman et al -catenin signaling in 
cytokine-stimulated chondrocytes reduced cartilage degradation. Similarly, our results 
confirmed the involvement of Wnt related genes and proteins with the anti-inflammatory 
effect (Fig 3.7). In addition, the anti-catabolic effect of GalNAc-a increased 
chondrogenic-specific gene expression and the proteoglycan and ECM production in the 
3D culture, indicating its chondroprotective effect on the OA chondrocytes (Fig 3.8). 
GalNAc-a’s aforementioned ability to inhibit the inflammation combined with its ability 
to promote chondrogenesis associated with the modulation of Wnt activity, makes it a 
strong potential candidate as a DMOAD to be efficacious under pathophysiological 
conditions. Further target identification and mechanistic studies of GalNAc-a action on 
the molecular signaling pathways are under way.  
In consideration of the fact that GalNAc-a exhibited the enhanced chondrogenic 
and chondroprotective effects on cartilage, we evaluated the potential of OA disease 
modifying interventions in surgically induced OA rat model. The histological 
assessments showed that the multiple weekly GalNAc-a treated rats showed improved 
cartilage repair of the damaged joints (Fig 3.9). Despite IA injection of therapeutics 
would be suitable for local drug delivery without the risk of systemic side effects, rapid 
clearance of IA injected drugs through the draining lymphatic system of the synovial 
fluid limits residence time of the drugs within knee (1-5 hours) [27]. In light of these 
restrictions, GalNAc-a was encapsulated in PLGA (poly(lactic-co-glycolic acid)) 




used as drug delivery carrier because of their excellent biocompatibility and 
biodegradability. It has been reported that PLGA microspheres can maintain optimal 
systemic concentration of drugs for months in the joint. Our results showed sustained 
release profiles of GalNAc-a from PLGA-GalNAc-a microspheres for over a month in 
vitro. While the systemic exposure of the IA injected GalNAc-a in a joint will be further 
investigated, we confirmed that a single IA injection of the PLGA-GalNAc-a 
microspheres one week after OA induction improved cartilage repair, which is 
comparable to the results observed in the multiple treatments of GalNAc-a (Fig 3.9D). 
Altogether, the in vitro and in vivo results support anabolic capacity of GalNAc-a on 
cartilage matrix to prevent OA progression. Further in vivo studies are under way to 




We found a sugar based compound, GalNAc-a that has enhancing chondrogenic 
and chondroprotective capacity. The dual benefits of GalNAc-a on MSC and 
chondrocytes could improve cartilage tissue production in vitro and cartilage repair in 
damaged joints in vivo. Furthermore, its incorporation into the microsphere drug delivery 
system showed efficient therapeutic outcomes without multiple injections. These findings 














Figure 3.1 Osteoarthritis (OA) is the degenerative joint disease with trauma and 
aging. The characteristics of OA include an irreversible loss of articular cartilage, 
subchondral bone thickening, osteophyte formation (bony projections that form along 






Figure 3.2 Limitation of current OA treatments. Current OA treatments are limited to 
symptomatic control including non-steroidal anti-inflammatory drugs, intra-articular 
injections of hyaluronic acid, or total knee replacement. These treatments focus on short-








Figure 3.3 3,4,6-O-Bu3GalNAc promoted chondrogenesis of hMSCs. Cells were 
treated with or without GalNAc-a (100 μM) in chondrogenic medium for two days. A. 
Chemical structure of 3,4,6-O-Bu3GalNAc. B. Gene expression level of chondrogenic 
markers SOX9 and AGGRECAN. C. Expression levels of Wnt-related genes AXIN2 and 
β-catenin. Data in (B and C) are averages of three individual samples relative to β-ACTIN 
mRNA. (*P<0.05, ***P<0.001). D. Protein expression of β-catenin in cytoplasmic and 
nuclear compartments was confirmed by Western blotting. β- -tubulin were 
used as respective loading controls. E. Immunofluoresence staining for cytoplasmic β-
  























































































Figure 3.4 Treatment of 3,4,6-O-Bu3GalNAc increased chondrogenic markers of 3D 
pellets of hMSCs and cartilage ECM production. Pellets were treated with or without 
3,4,6-O-Bu3GalNAc  (100 μM) in the chondrogenic medium for 21 days. A. Gene 
expression level of chondrogenic markers, SOX9, AGGRECAN, and TYPE II 
COLLAGEN (COLLAGEN II). Data are averages of three individual samples relative to 
β-ACTIN mRNA (* P<0.05, ** P<0.01). B. DNA contents normalized to dry weight. C. 
sGAG contents normalized to the DNA content.  Data in (B and C) are averages of three 






Figure 3.5 3,4,6-O-Bu3GalNAc treatment increases chondrogenic expression and 
cartilage ECM deposition by hMSCs encapsulated in 3D hydrogels. The hydrogels 
were incubated with or without 3,4,6-O-Bu3GalNAc (100 μM) in chondrogenic medium 
for 21 days. A. Gene expression levels of chondrogenic markers SOX9, AGGRECAN, and 
TYPE II COLLAGEN (COLLAGEN II). Data are averages normalized to GAPDH (n = 3, 
* P<0.05, ** P<0.01). B. Biochemical analysis of DNA content, normalized to dry 
weight. C. GAG content, normalized to the DNA content. Data in (B and C) are averages 
of three individual samples. D. Safranin-O and immunohistochemical staining (type II 





Figure 3.6 3,4,6-O-Bu3GalNAc reduces osteogenic capacity of hMSCs. Cells on 
monolayer and 3D hydrogel cultures were incubated with or without 3,4,6-O-
Bu3GalNAc in the osteogenic medium. A. Alkaline phosphatase (ALP) activity (scale 
, ), and Oil red O (ORO, scale bar: 100 
B. RT-PCR analysis of gene expression after 5 days osteogenic induction of 
hMSCs. C. RT-PCR analysis of osteogenic markers at 10 days of the osteogenic 
induction. D. RT-PCR analysis of adipogenic markers at 15 days of the osteogenic 
induction. For RT-PCR analysis, β-ACTIN mRNA was used as a control and three 
individual samples were collected and averaged (* P<0.05, ** P<0.01, *** P<0.001). E. 
-PCR analysis 
of osteogenic markers after 21 days osteogenic induction of hMSCs encapsulated in the 






Figure 3.7 3,4,6-O-Bu3GalNAc exerts an anti-inflammatory effect on human OA 
chondrocytes. Primary human OA chondrocytes were cultured in chondrogenic medium 
supplemented with IL-1β for 24 h and then further incubated with or without 3,4,6-O-
Bu3GalNAc (100 μM) in the presence of IL-1β for another 24 h. A. Gene expression of 
inflammatory markers and B. Wnt signaling genes. Data are averages normalized to β- 









Figure 3.8 3,4,6-O-Bu3GalNAc increased chondrogenic markers and cartilage ECM 
production in 3D hydrogel culture. The hydrogels were incubated with or without 
3,4,6-O-Bu3GalNAc (100 M) in the presence of IL-1β for 21 days. A. RT-PCR analysis 
of inflammatory markers, B. chondrogenic markers, and C. Wnt related markers 
(endogenous mRNA control: GAPDH, n = 3, * P<0.05, ** P<0.01, *** P<0.001). D. 
Biochemical analysis of DNA contents and E. sGAG, normalized to the DNA content (n 
= 3).  F. Safranin-O and immunohistochemical staining (type II collagen) of cross-section 






Figure 3.9 3,4,6-O-Bu3GalNAc increased chondrogenic markers and cartilage ECM 
production in 3D hydrogel culture. The hydrogels were incubated with or without 
3,4,6-O-Bu3GalNAc (100 μM) in the presence of IL-1β for 21 days. A. RT-PCR analysis 
of inflammatory markers and B. chondrogenic markers (endogenous mRNA control: 
GAPDH, n = 3, * P<0.05, ** P<0.01, *** P<0.001). C. Biochemical analysis of DNA 
contents and D. sGAG, normalized to the DNA content (n = 3).  E. Safranin-O and 






Figure 3.10 Cartilage repair of OA induced rats by intra-articular injection of 3,4,6-
O-Bu3GalNAc. A. Representative safranin-O stained histological images of the tibial 
plateau to evaluate the pathological changes 4 weeks after medial meniscal transection 
(scale bar -GalNAc group was given IA injections of 3,4,6-O-
Bu3GalNAc on days 7, 14, and 21 after the OA surgery. The Single-3,4,6-O-Bu3GalNAc, 
PLGA, and PLGA-3,4,6-O-Bu3GalNAc groups were given IA injections on days 7 after 
the surgery. B. Comparison of the tibial plateau joint based on the OARSI scoring system 
(n = 3~6, ** P<0.01, *** P<0.001). C. The size distribution of PLGA-3,4,6-O-
Bu3GalNAc and scanning electron microscopic image of fabricated PLGA-3,4,6-O-
Bu3GalNAc microspheres (scale D. The cumulative in vitro release profile 
showed sustained release of 3,4,6-O-Bu3GalNAc (sugar) from PLGA-3,4,6-O-
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Osteoarthritis and Senescent cells  
OA is generally considered a degenerative disease of joints with aging since the 
incidence of OA increases with increasing age but younger populations are at risk in the 
case of post-traumatic OA. The characteristics of OA include an irreversible loss of 
articular cartilage, subchondral bone thickening, osteophyte formation, and local joint 
inflammation[1]. Current pharmacologic OA treatment options are analgesics, non-
steroidal anti-inflammatory drugs, and viscosupplementation (e.g. hyaluronic acid (HA)) 
with intra-articular (IA) injections[2].  These treatments focus on short-term symptomatic 
pain relief, however with advances in the understanding of the OA pathogenesis there is a 
focus now on disease-modifying OA drugs (DMOADs) designed to block or reverse OA 
progression by targeting specific OA catabolic pathways and pathophysiological 
signaling pathways[3]. Examples of other therapeutic strategies to treat OA include the 
biologic platelet-rich plasma, Lubricin, HA and biomimetic aggrecan IA injections[4]. 
Cellular senescence is defined as an irreversible proliferation arrest. It prevents 
the proliferation of damaged and dysfunctional cells, thereby protecting multicellular 
organisms against cancer development[5, 6]. However Senescent cells (SnCs) can also 
contribute to the tissue deterioration that underlies aging and many age-related 




where they promote age-related phenotypes and pathologies, presumably through the 
senescence-associated secretory phenotype (SASP)[7]. The SASP is the transcriptional 
upregulation and secretion of several extracellular proteases, pro-inflammatory cytokines, 
chemokines and growth factors[8, 9]. Removal of SnCs in the progeroid mouse model 
delays several pathologies and increases healthy life span in normal mice [10, 11]. In the 
case of cartilage, senescent chondrocytes are associated with both post-traumatic and age-
related OA as they have been found in cartilage tissue isolated from patients with OA 
undergoing joint replacement surgery.  
A number of the senescence associated molecular pathways have been defined. 
SnCs induced by stress share common stress-response signaling and senescence 
activation molecular pathways[12]. The first pathway is activated by DNA-damaging 
stressors, which stabilize the tumor suppressor protein 53 (p53) and upregulate the p53 
transcriptional target p21[13]. Then p21 prevents cyclin-dependent kinase 2 (CDK2)-
mediated inactivation of retinoblastoma (RB), which prevents the cells from entering the 
cell cycle phase S. A second pathway is the p16 INK4a–retinoblastoma protein (pRB) tumor 
suppressor pathway. Senescence signals induce the expression of p16INK4a, an inhibitor 
of CDK. Then CDK further prevents pRB phosphorylation and inactivation, which stops 
cells from proliferating. Despite the complementary relationship between these two 
pathways, senescent cells may have distinct responses depending on which pathway is 
responsible for their development, and this may evolve over time.  
 SnCs, through their SASP, can also provide beneficial signals for a number of 
biological processes including the development of embryonic structures[14], wound 




found among chondrocytes, the major cellular component of articular cartilage, of older 
OA patients. These cells express matrix-degrading enzymes that include SASP factors. In 
vitro studies have shown that the senescence marker p16 INK4a was expressed in human 
OA chondrocytes and triggered osteoarthritic cell/tissue changes such as increased gene 
and protein expressions for matrix metalloproteinases (MMPs), cartilage degradation, and 
cartilage calcification[18, 19]. SnCs have been also found after cellular trauma[20]. For 
example, when young chondrocytes were exposed to oxidative stress in vitro (mimicking 
the release of reactive oxygen species following joint trauma), they underwent 
cumulative and accelerated senescence. The secretion profile of SnCs and their presence 
in human OA cartilage strongly suggest that cellular senescence contributes to the age-
related and traumatic changes in the chondrocytes and joint tissues with OA. 
While the presence of SnC in age-related and traumatic OA has been observed, the 
removal of these cells as a treatment for OA has not yet been considered or realized. 
Provided herein are the methods and results of further investigation into how senescent 
cells can affect cellular processes related to OA. In this study, how senescent cells 
contribute to OA progression and an investigation into therapeutic benefit of clearing 
these cells by using GCV in p16-3MR transgenic mice and UBX0101 in wild type 
C57BL/6 mice.  
 
4.2 Materials and Methods  
Mice generation and drug treatment  
We purchased young (10-week-old) male C57BL mice from Charles River 




as previously described[16] and were bred in the animal facility of the Johns Hopkins 
University School of Medicine. All studies described using INK-ATTAC mice (a 
C57BL/6J strain) were generated and performed as previously described[10]. The 
experimental protocol was approved and performed in accordance with the Institutional 
Animal Care and Use Committee at Johns Hopkins University and the Mayo Clinic 
Institutional Animal Care and Use Committee.  All mice were housed under pathogen-
free conditions, with 5 or less mice per cage.  Mice had free access to food and water.  
The mice used for all experiments were randomly assigned to control or treatment groups, 
and those used in OA evaluation.  For drug treatments, p16-3MR and normal C57BL 
mice were injected intra-articularly (IA) with 1 or 2 mM of GCV (Sigma-Aldrich, USA, 
#G2036) in 10 μl of saline or 0.2, 1, or 5 mM of UBX0101 in 10 μl of saline. INK-
ATTAC mice were administrated intraperitoneally 2.0 μg AP20187 (B/B homodimerizer, 
Clontech, USA) per g body weight or vehicle from 12 months until the end of life.  
Cell isolation and culture 
Human articular cartilage samples explanted from OA patients undergoing total 
knee arthroplasty were received from the National Disease Resource Institution 
(Philadelphia, USA) according to an IRB-approved protocol.  The cartilage tissue was cut 
into 1mm3 pieces, washed 3 times with phosphate-buffered saline (PBS) supplemented 
with 100 U/mL penicillin and 100 μg/mL streptomycin (Pen/Strep; Invitrogen, USA, 
#15140-122), and digested on an orbital shaker for 16 h at 37 °C with 0.17% (w/v) type II 
collagenase (Worthington Biochemical, USA, #4176) in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco, USA, #11965-092) with 10% fetal bovine 




through a 70 μm strainer and cells were rinsed 3 times with DMEM supplemented with 
1% Pen/Strep and 10% FBS. For 3D pellet culture of human OA chondrocyte[21], 
400,000 cells were seeded in 96 well MicroWell™ round bottom plates (Thermo Fisher 
Scientific, USA). The pellets were formed in the bottom by centrifugation at 150xg for 10 
min.  The human OA chondrocytes pellets were maintained at 37 °C with 5% CO2 in 200 
μl of chondrocyte growth medium consisting of high-glucose DMEM, 1% Pen/Strep, 
10 % FBS, 1% NEAA (Gibco, USA, #11140-050), 1 M HEPES (Gibco, USA, #15630-
080), 100 mM Sodium pyruvate (Gibco, USA, #11360-070), 0.2 M L-Proline (Sigma, 
USA, #P5607), and 25 mg/ml ascorbic acid (Sigma, USA,  #A5960). Pellets were 
harvested after 21 days for evaluation.  The media were changed 3 times a week until the 
end of the experiment.  
Surgically induced OA mouse model 
Anterior cruciate ligaments transection (ACLT) and sham surgery were 
performed on 10-week old or 19-month old male p16-3MR and 10-week old C57BL 
mice.  Animals were placed under general anesthesia with 3% isoflurane, and the hind 
limbs shaved and prepared for aseptic surgery.  For the sham operation, the knee joint 
was exposed following a medial capsular incision, which cuts the patellar tendon and 
surgical skin incision was closed with suture. For the ACLT surgery, after opening the 
joint capsule, the ACL were transected with micro-scissors under a surgical microscope.  
After irrigation with saline to remove tissue debris, the skin incision was closed.  All 
procedures were performed according to the Institutional Animal Care and Use 
Committee at Johns Hopkins University School of Medicine.  On week 4, 8 or 12, the 




histological assessment of the medial tibial plateau joint through blinded graded 
observations by 2 observers, according to the Osteoarthritis Research Society 
International (OARSI) Scoring System[22].  
Bioluminescence 
For in vivo luminescence imaging, p16-3MR mice were injected intra-articular 
with 10 μl (150 μg/ml) of Xenolight RediJect Coelentarazine h (Calipers, Waltham MA, 
USA).  Twenty-five minutes later, the mice were anesthesized with isofluorane and 
luminescence was measured with a PerkinElmer IVIS SpectrumCT in vivo imaging 
System (Caliper Life Sciences, Hopkinton MA, USA; 5 minutes, medium binning).   
Real time RT-PCR 
To extract RNA, the operated and control hind limbs were dissected and 
immediately transferred to liquid nitrogen and then pulverized with mortar and pestle.  
Total RNA was extracted from the knee joints using Trizol reagent and reverse 
transcribed to cDNA using Super-Script II reverse transcriptase following the 
manufacturer’s protocol (Invitrogen, CA, USA).  Real-time PCRs for cdkn2a, cdkn1a, 
il1β, mmp3, mmp13, col2a1, acan, sox9, runx2, opg, bglap, rankl and ctsk were 
performed using the StepOnePlus Real Time PCR System with SYBR Green PCR Master 
Mix (Applied biosystems by Life technologies, USA, #4367659).  All signals were 
normalized to β-actin. Relative gene expression was calculated by the ΔΔCt method 
where the ΔCt was calculated using the β actin reference gene.  ΔΔCt was calculated 
relative to the unoperated control group in in vivo studies and relative to control samples 





Mice were placed on the hotplate analgesia meter at 55 °C (Columbus 
Instruments, USA).  The latency period for hindlimb response (for example, shaking, 
jumping or licking) was recorded as response time before and at different time points 
after surgery[23] At least three measurements are taken per mouse. The observer was 
blinded to the genotype and the treatment of the mice. 
Weight bearing 
Static incapacitance measurements were performed using Incapacitance Tester 
(Columbus Instruments, USA). Mice were first acclimated to the chamber at least 3 times 
before measurement.  After acclimitization, mice were maneuvered inside the chamber to 
stand with one paw on each scale.  Weight placed on each hind limb was measured over a 
3-second interval for at least 3 separate measurements.  Results are expressed as a 
percentage of weight placed on the operated limb versus contralateral control limb.  The 
observer was blinded to the genotype and treatment of the mice. 
Pharmacokinetic half-life determination 
Local and blood pharmacokinetics was performed after a single intra-articular 
administration of 1 mM UBX0101 in saline to determine the half-life and were generated 
by Seventh Wave laboratories (MO, USA).  
Biochemical analysis for GAG contents 
The pellets (n = 3 per group) were lyophilized for 2 days and then digested 




sulfated glycosaminoglycan (sGAG) content was determined by 1,9-dimethylmethylene 
blue (DMMB) dye assay, measuring absorbance at 525 nm and using chondroitin sulfate 
as a standard.  DNA content was determined by the Hoescht Dye 33342 DNA assay, 
using calf thymus DNA as a standard.  GAG content levels were expressed as 
micrograms of GAG per microgram of DNA. 
Histology 
The pellets and mice joints were fixed in 4% paraformaldehyde overnight, 
dehydrated in increasing concentrations of ethanol, and embedded in paraffin.  Five 
micrometer-thick sections were cut from the paraffin block and collected onto glass slides.  
The sections were stained for proteoglycans with aqueous Safranin-O (0.1%) for 5 mins 
and then the specimens were mounted.   
Quantification of subchondral bone damage 
Osteophyte thickness (a distance on the marginal zone of medial tibial plateau 
starting an original edge of the tibial articular cartilage) was measured with AxioVision 
SE64 software. Medial tibial bone sclerosis (the extent of subchondral bone 
sclerosis/reduction in bone marrow area) was scored by measuring subchondral 
trabecular bone to marrow ratio. On each safranin-O stained joint section, the decrease or 
increase in trabecular bone area was assigned a score from -5 to 5, where 0 represents no 





For immunohistochemical staining, endogenous peroxidase of the sections was 
quenched using 2.5% (v/v) hydrogen peroxide in methanol, then incubated at 3° C with 
0.25% (w/v) hyaluronidase for 1 h.  The AEC Broad Spectrum Histostain-SP Kit 
(Invitrogen, USA, #959944) was used following the manufacturer’s instructions.  
Primary antibodies for p16INK4a (1:500;Abcam, USA, #ab54210), MMP-13 (1:200; 
Abcam, USA, #ab39012), type I collagen (1:100; Abcam, USA, #ab34710), type II 
collagen (1:300; Abcam, USA, #ab34712), and type X collagen (1:50; Abcam, USA, 
#ab58632), osteocalcin (1:100; Millipore, USA, #AB10911), HMGB1 (1:500; Abcam, 
USA; #ab18256), Ki67 (1:100; Novusbio, USA, #NB110-89717) and PCNA (1:100; 
Thermo scientific, # MA511358) were used and dilution in 4% BSA dissolved in PBST.  
Immunofluorescence 
Monolayer cultures of human OA chondrocytes were fixed in 4% 
paraformaldehyde, permeabilized with PBS containing 0.25% Triton X-100 for 10 min, 
then blocked with 4% BSA containing 0.25% Triton X-100 for 30 min at room 
temperature.  The cells were incubated with primary antibodies against HMGB1 (1:100; 
abcam, USA) overnight at 4°C.  The cells were rinsed 3 times with PBS and incubated 
was goat anti-rabbit IgG (H& L) conjugated with Alexa Fluor 594 (1:1000; Life 
technologies, USA, #A-11012).  After washing, the nuclei were counterstained with 
DAPI for 5 min.  Nuclear HMGB1 was imaged by fluorescence microscopy (Carl Zeiss, 
USA). Cell proliferation was detected using Click-iT® EdU (5-ethynyl-2'-deoxyuridine) 
Alexa Fluor® 488 imaging kits (Promega, USA, #C10337).  Total cells were counted 
following nuclear DAPI counter staining in 10 random fields per culture dish to 





SA-β-gal staining was done using a kit (Biovision, USA, #K320-250) according 
to the manufacturer’s instructions.  SnCs were identified as blue-stained cells under light 
microscopy.  Total cells were counted using a nuclear DAPI counterstain in 10 random 
fields per culture dish to determine the percentage of SA-β-gal positive cells.   
Flow cytometry analysis for apoptosis detection 
For Annexin V/PI analysis, live trypsinized and floating cells were collected, 
centrifuged, rinsed with PBS. Cells were stained with Annexin V apoptosis detection kit 
APC according to the manufacturer’s instructions (eBioscience, USA, #88-8007).  Data 
were analyzed with the BD AccuriTM C6 flow cytometer and FlowJo X 10.0 software 
(Becton Dickinson, USA).   
Western blot 
To assay the cleaved caspase-3, and p16INK4a protein, chondrocytes were 
harvested, washed twice with ice-cold PBS, and lysed with RIPA buffer (Thermo 
Scientific, USA, #89900) containing protease (Sigma, USA, #P8340) and phosphatase 
inhibitor mixture (Sigma, USA, #P5726) according to the manufacturer’s instructions. 
Total proteins concentration was determined using the BCA assay (Pierce, USA, #23227). 
Protein were separated by 10% SDS-PAGE and then transferred onto nitrocellulose 
membranes. The membranes were blocked for one hour with 5% BSA in Tris-buffered 
saline containing 0.1% tween-20 (TBST) and incubated overnight at 4°C with primary 
antibody specific for cleaved caspase-3 (1:1000, Cell signaling, USA, #9661), p16INK4a 




unbound primary antibodies, the membranes were incubated with horseradish peroxidase-
conjugated anti-rabbit secondary antibodies (1:5000, Bio-Rad, USA) and anti-mouse 
secondary antibodies (1:5000, Cell signaling, USA, #7076) and proteins were detected by 
ECL.  
Statistics 
The data displayed normal variance. No statistical method was used to predetermine 
sample size except early death of mice due to fighting. The experiments were not 
randomized, except for the in vivo animal studies with mice as described above. Any 
samples and animals didn’t exclude from the analysis. All in vivo data are expressed as 
mean and each data point represents an individual mouse. All in vitro data are expressed 
as are averages ± S.D. Statistical significance (p value) was determined by an unpaired, 
two-tailed Student t test with Welch’s correction (we do not assume equal S.D. in each 
group) or one-way ANOVA (Tukey’s multiple comparison test). All analyses were 
performed by Prism 6 from GraphPad software (San Diego, CA, USA).  Statistical 
significance was determined to be P < 0.05.  
 
4.3 Results and Discussion 
To critically test the idea that SnCs contribute to OA pathogenesis, we first asked 
whether SnCs develop after articular joint injury in mice by following the expression of 
p16INK4a (also known as cyclin-dependent kinase inhibitor 2a, encoded by the cdkn2a 
locus), a frequently used biomarker for SnCs[6, 10, 13, 24]. We induced post-traumatic 




invasively monitored[16],[25] (Fig 4.3a). Luminescence in the articular joint region of the 
p16-3MR mice increased after ACLT surgery (Fig. 4.4a, b), peaking two weeks post-
injury and decreasing thereafter to a low level steady state that remained above 
background (Fig. 4.3b). The mRNA level of cdkn2a increased and decreased with 
kinetics similar to that of the luminescence (Fig. 4.4c and Fig. 4.3c). mRNA levels of 
cdkn1a and the SASP marker interleukin (il)6[12] also increased in vehicle-treated ACLT 
mice compared to sham-operated controls 28 days after ACLT, further corroborating the 
development of SnCs in the injured joint (Fig. 4.3d). OA disease and cartilage 
degeneration after ACLT was confirmed histologically and through pain assessment. 
ACLT injury reduced Safranin-O proteoglycan staining with cartilage thinning and 
surface irregularities and induced type 2 collagen degradation (Fig. 4.3e, f). Behavioral 
assessment of OA-induced pain showed that ACLT surgery caused mice to decrease 
weight bearing on the injured leg and increase the latency period for the injured hind limb 
to reach a pain threshold after placement onto a 55°C platform (Fig. 4.3g). 
 To localize SnCs in the articular joint, we performed immunostaining for p16 INK4a 
protein and loss of nuclear high-mobility group box 1 (HMGB1) – an extracellular 
alarmin that precedes the secretion of SASP components in cells undergoing 
senescence[26, 27]. In vehicle-treated ACLT mice, p16INK4a protein was largely restricted 
to the superficial zone, where 66% of cells were p16 INK4a-positive and 65% of cells had 
little to no nuclear HMGB1 staining in the articular cartilage (Fig. 4.4e, f). In contrast, 
there were lower numbers of cells that stained for p16 INK4a protein and HMGB1 was 
largely nuclear in sham-operated controls. In addition to the cartilage surface, an increase 




apparent increase of p16INK4a expression in the infrapatellar fat pads in vehicle-treated 
p16-3MR ACLT mice compared to those without ACLT surgery (Fig. 4.5a). The role of 
the synovium in OA has long been postulated[28], and these results suggest it also 
contributes to the senescence burden in articular joints during OA progression. SnC 
localization in the superficial layer of cartilage has particular significance for tissue 
regeneration, as this is where purported cartilage progenitor cells are located[29]. 
Furthermore, the superficial and deep cartilage layers interact to maintain homeostasis 
and increase new tissue production when needed[30], further indicating a regulatory role 
of these superficial layer cell populations that express p16 INK4a.   
 Next, we sought to determine whether selective removal of SnCs that develop 
after ACLT reduced or reversed the progression of OA and OA-related symptoms.  We 
took advantage of the p16-3MR transgene that also includes the truncated herpes simplex 
virus 1 (HSV-1) thymidine kinase (HSV-TK) that permits the selective killing of 
p16INK4a-expressing cells by ganciclovir (GCV)[31]. To clear SnCs, we reduced the 
number of GCV injections into the joint (2 cycles of 5 consecutive injections in Fig. 4.3) 
to once every two days starting at day 14 after ACLT surgery (Fig. 4.4a). GCV treatment 
reduced luminescence in the ACLT mice (Fig. 4.4b), indicative of clearing p16 INK4a-
positive SnCs. Clearance was confirmed by reduced injury-induced increases in the 
mRNA levels of cdkn2a and cdkn1a (Fig. 4.4c, d), along with increased immunostaining 
for nuclear HMGB1 and reduced p16 INK4a protein in the cartilage (Fig. 4.4e, f). We also 
observed a reduction in p16INK4a expression in the synovium in GCV-treated p16-3MR 
mice (Fig. 4.5a). Clearance of SnCs inhibited articular cartilage erosion such that 




g). Pain associated with the ACLT injury also decreased when SnCs were removed (Fig. 
4.4h), as was expression of the inflammatory markers matrix metalloproteinase (mmp)13 
and il1β (Fig. 4.4d) that are typical of OA disease and tissue degradation[32]. SnC 
removal increased expression of proteins and col2a1 and acan mRNA (which encode the 
cartilage extracellular matrix molecules type II collagen and aggrecan). The expression of 
sox9, which among other activities regulates chondrogenesis, remained unchanged. 
However, pathological changes in the subchondral bone and expression of bone 
resorption-related genes[33] increased after ACLT surgery and OA development but 
were not rescued by GCV treatment (Fig. 4.5b–d), suggesting that GCV may not reach 
the bone when injected intra-articular and systemic administration may be required[25]. 
To confirm that GCV itself did not influence the local cartilage environment but only 
killed SnCs in p16-3MR mice, we injected GCV into ACLT-treated joints of non-
transgenic C57BL mice where it was found to have no influence on OA disease 
progression or pain (Fig. 4.3). Together these data suggest that SnCs develop after trauma 
in the articular cartilage and synovium of the knee joint, and their removal, even after OA 
and symptoms developed, reduces disease impact and creates a pro-chondrogenic 
environment.   
 To selectively clear SnCs using a pharmacologic approach, we tested a senolytic 
(UBX0101) that was recently identified for selective elimination of SnCs[25, 34].  First, 
we optimized the concentration of UBX0101 using p16-3MR mice using an injection 
regimen similar to that used to administer GCV. The development of SnCs was followed 
by luminescence to compare drug efficacy in clearing SnCs with that of GCV. An IA 




SnCs induced by the surgery.  The luciferase signal decreased after UBX0101 treatment 
(Fig. 4.6a) and SnC clearance was confirmed by reduced expression of cdkn2a, cdkn1a, 
mmp13 and il1β (up to 50%) in UBX0101-treated ACLT mice (Fig. 4.6b). OA-related 
disease outcomes of pain and articular cartilage erosion were similarly reduced with both 
compounds (Fig. 4.6c–e).  Proteoglycan loss, thinning and calcification of articular 
cartilage were attenuated in ACLT mice treated with 1 mM UBX0101. Moreover, 
injection of 0.2 to 5 mM UBX0101 also produced a pro-chondrogenic environment 
characterized by increased col2a1 and acan gene expression, indicating new cartilage 
growth.  The expression of sox9 and runx2, which regulates chondrocyte hypertrophy and 
bone development[35], remained unchanged (Fig. 4.6b). Similar to the GCV response in 
the p16-3MR mice, abnormal subchondral bone remodeling and osteophyte formation in 
ACLT mice were not rescued by UBX0101 treatment.  
 The lifetime of UBX0101 in the articular joint is short, with concentrations falling 
below the IC50 after 1.5 hours. Systemic exposure is minimal (3.3% of IA dose reaches 
the circulation) and the IC50 is never reached (Fig. 4.7). This short half of UBX0101 in 
the joint cavity was effective in blocking cartilage erosion in our ACLT mouse model 
because UBX0101 eliminates SnCs rather than blocking their secretion. Once the cells 
have been eliminated, drug exposure is no longer necessary. Considering therapeutic 
translation, we next aimed to reduce the number of IA injections while still achieving 
successful SnC removal. We thus determined the number of UBX0101 injections (once 
every two days) required to reduce OA progression when injected 14 days after ACLT 




of cdkn2a, mmp13 and il1β, increased the expression of col2a1 and acan, and reduced 
OA-induced pain compared to vehicle-treated ACLT mice.  
 We next confirmed the efficacy of IA UBX0101 injections for treating ACLT-
induced OA in C57BL mice.  Based on the short drug lifetime in the articular space and 
the dosing experiments, six IA injections (1 mM, once every two days starting at day 14 
after ACLT over 2 weeks) were performed (Fig. 4.9a).  Similar to the effects of GCV in 
p16-3MR mice, UBX0101 treatment selectively killed SnCs that were induced by ACLT 
surgery in the articular cartilage. This SnC clearance was confirmed by (i) a reduced 
number of cells without nuclear HMGB1 and increased numbers of nuclear HMGB1 + 
non-SnCs (Fig. 4.9b, c); ii) an increased number of p16INK4a, Ki-67 and proliferating cell 
nuclear antigen (PCNA) expressing non-SnCs (Fig. 4.9b, c and 4.10a); (iii) fewer 
mmp13-positive chondrocytes (Fig. 4.9b, c); and iv) reduced levels of cdkn2a, cdkn1a, 
il6 and mmp13 mRNAs 28 days post-injury (Fig. 4.9d). We also observed fewer Ki-67-
expressing cells in the synovium of the vehicle-treated C57BL mice, consistent with the 
presence of SnCs, which was abrogated by UBX0101 treatment (Fig. 4.10b). This 
correlates with a reduction in expression of p16INK4a in the synovium of the GCV-treated 
p16-3MR mice.  
The long-term durability of a single UBX0101 treatment course, and its ability to 
attenuate articular cartilage degeneration and ameliorate OA symptoms, was evaluated 
over 84 days (Fig. 4.9c–f, 4.11 and 4.12). Pain reduction was maintained between 28 and 
56 days after surgery and pro-chondrogenic gene and protein expression of col2a1 and 
acan remained upregulated compared to the untreated control. Subchondral bone 




OA-induced pain and disease (cartilage degradation and subchondral bone sclerosis) 
returned at 84 days after ACLT or 4 weeks after the last drug injection (Fig. 4.12), 
suggesting that SnCs may return by week 12 after ACLT.  In the mouse ACLT, the 
ligament cannot be repaired so continued damage may occur in the joint in addition to 
age-related accumulation of SnCs that develop over time. Thus, repeated treatment may 
be required to remove SnCs that accumulate due to injury and aging to prevent disease 
development and achieve long term disease modification.   
To test the potential of treating later stage disease, we injected UBX0101 42 days 
after ACLT (Fig. 4.13a).  After the standard IA injections over two weeks, UBX0101 
treatment increased the number of non-SnCs with nuclear HMGB1 (Fig. 4.13b), reduced 
OA-induced pain (Fig. 4.13c), and reduced the levels of cdkn2a, cdkn1a, and mmp13 
mRNAs (Fig. 13d).  Further, chondrogenic gene expression (col2a1 and acan mRNAs) 
and proteoglycan staining in the articular cartilage increased even with the late UBX0101 
treatment (Fig. 4.13d, e). ACLT mice treated with UBX0101 had a reduction in 
subchondral bone sclerosis but similar osteophyte formation relative to vehicle treated 
controls (Fig. 4.13f). Together these results indicate the UBX0101 can clear SnCs from 
articular cartilage to reduce OA symptoms and modify the disease by creating a pro-
regenerative environment even in later stage disease.   
Similar to humans, aging contributes to the development of spontaneous and 
injury-induced OA in mice[36, 37]. We therefore explored the consequences of selective 
removal of naturally occurring, age-related SnCs on arthritis development using the INK-
ATTAC transgenic model that was previously reported[10, 11]. Starting at 12 months of 




injected intraperitoneal in female mice twice a week until animals became moribund. In 
the articular joints of these mice, elimination of naturally occurring p16 INK4a-positive 
SnCs markedly reduced aged-related cartilage degeneration compared to vehicle alone in 
the INK-ATTAC transgenic mouse as demonstrated by significantly increased Safranin-
O staining for proteoglycans, cartilage thickness, and normalized Osteoarthritis Research 
Society International (OARSI) scores (Fig. 4.14a–c and 4.15a).  
The synergistic impact of age and trauma may further exacerbate disease. To 
address this we performed the ACLT surgery on mice aged 19 months and evaluated the 
effect of selective SnC removal on OA disease. Contrary to young animals, luminescence 
in the articular joint region of vehicle-treated aged p16-3MR mice increased continually 
over 28 days after ACLT surgery (Fig. 4.14d). This SnC development in ACLT mice was 
corroborated by significant increases in cdkn2a, cdkn1a and the SASP factor il1β and 
increased ki-67 positive non-SnCs compared to no surgery controls (Fig. 4.14e and 
4.15b). Moreover, distribution of the SnCs after ACLT was significantly different from 
the young mice. In particular, 40% of p16 INK4a-positive SnCs were localized throughout 
the articular cartilage of vehicle treated-ACLT mice instead of only the superficial layer 
(Fig. 4.14e and 4.15b).  
More severe OA developed after ACLT surgery in the aged 3MR mice compared 
to young mice as demonstrated by histology and OARSI scoring of vehicle treated 
animals (Fig. 4.14f, g).  In fact, the baseline morphology of the aged animals without 
surgery showed thinning cartilage with reduced Safranin-O staining and higher OARSI 
scores. Removal of SnCs from the aged 3MR animals using the standard regimen of 




Furthermore, gene expression for cdkn2a, cdkn1a, il6 and mmp13 was reduced with SnC 
clearance. Moreover, cdkn2a, cdkn1a and mmp13 gene expression levels in mice with 
ACLT treated with UBX0101 were lower than animals that did not receive any surgery, 
suggesting higher baseline levels of SnCs in the aged mice (Fig. 4.14f).  Contrary to the 
young animals though, there was no increase in pro-chondrogenic gene expression 
(col2a1 and acan mRNA) in the older animals after treatment at 28 days (Fig. 4.14f). 
Histologically, there was a small increase in Safranin-O staining of the articular cartilage 
in ACLT mice but the decrease in OARSI scoring was not statistically significant with 
the small number of animals in this study. ACLT- and age-induced changes in bone did 
not significantly change with UBX0101 treatment (Fig. 4.15c, d). However, SnCs found 
in the synovium were cleared with UBX0101 treatment and those in the subchondral 
bone marrow were slightly reduced (Fig. 4.15e). These findings suggest that UBX0101 
can clear SnCs from aged articular cartilage but the age-related decline in proliferative 
and synthetic capacity of articular chondrocytes may reduce subsequent tissue 
regeneration[38]. However, based on the drastic articular joint improvement in the 
significantly older animals with naturally occurring OA, it is likely that additional 
treatments, and potentially systemic treatment, may be required to reduce disease and 
rebuild tissue.  
 The relevance of SnCs and their clearance in clinical OA was evaluated in explant 
and in vitro cultures from patients undergoing total knee arthroplasty. To validate the 
presence of SnCs in human disease tissues, we performed senescence associated-β-
galactosidase (SA-β-gal) staining and HMGB1 immunhistochemistry on human arthritic 




depth of osteoarthritic cartilage and little to no nuclear HMGB1 staining in OA tissues 
compared to healthy controls (Fig. 4.16). However, staining was variable in cartilage 
tissue isolated from different regions of the joint within an individual patient, suggesting 
variability across the articular surface.  To avoid bias from this variability in SnCs across 
the articular joint, we isolated cells from the tissue for further testing.   
Exposure to the UBX0101 senolytic effectively cleared SnCs isolated from 
human OA cartilage in monolayer. Preliminary screening showed that 43 μM UBX0101 
killed senescent chondrocytes isolated from human OA tissue, as determined by the SA-
β-gal assay (Fig. 4.17). To further understand the effects of UBX0101, human OA 
chondrocytes were exposed to UBX0101 for 2 days (43 μM) (Fig. 4.17a); this regimen 
killed 20% of the SnCs and no more than 5% of non-SnCs, as determined by staining for 
SA-β-gal activity, nuclear HMGB1, and Annexin V—PI live-dead cell staining (Fig. 
4.17b, c).  Increased levels of activated caspase-3 suggest that UBX0101 kills SnCs 
through the apoptotic pathway in treated human OA chondrocytes (but not healthy 
chondrocytes, Fig. 4.17d and 4.18d). After human OA chondrocytes were exposed to 
UBX0101 for 2 days, followed by drug-free culture for 8 days, the cultures showed a 
decline in the expression of the senescence-related genes cdkn2a (without statistical 
significance), mmp3, and il6.  Protein levels of OA-related molecules – mmp13, and il1β 
also decreased (Fig. 4.17e). Furthermore, selective removal of SnCs from the OA 
chondrocyte cultures by UBX0101 increased proliferation of the remaining chondrocytes 
up to 15%, as determined by labeling of individual cells with 5-ethynyl-20-deoxyuridine 
(EdU) (Fig. 4.17f).  These data suggest that transient UBX0101 treatment may cause a 




proliferation after removal of UBX0101.   
 We next evaluated UBX0101 treatment of human OA chondrocytes in a three-
dimensional (3D) pellet system that supports maintenance of the chondrocyte phenotype 
and chondrogenesis. After 21-days of culture human OA chondrocyte pellet cultures, 
transiently (4-day) exposed to 43 μM UBX0101, dramatically reduced the level of SnCs 
(Fig. 4.17g), as determined by reduced SA-β-gal activity (Fig. 4.17h).  UBX0101 also 
reduced the levels of cdkn2a, mmp3, il1β and il6 mRNAs and increased levels of col2a1 
and acan (Fig. 4.17i).  Similarly, UBX0101 decreased protein levels of p16 INK4a and 
mmp13 and increased col2a1, proteoglycan and sulfated glycosaminoglycans (sGAG), 
confirming new cartilage growth (Fig. 4.17i, j).   
 
4.4 Conclusions 
In summary, we report the development of SnCs after articular joint injury in the 
superficial layer of cartilage and the synovium. These cells express a SASP that includes 
inflammatory molecules and degradative enzymes. The removal of SnCs, either using a 
transgenic mouse models or through pharmaceutical intervention that targets SnCs, 
reduced the development of post-traumatic OA and related pain, and created a pro-
chondrogenic environment. Aged animals had a higher senescence burden and developed 
more severe OA after injury. The relevance of our findings to human disease was 
validated using chondrocytes isolated from arthritic patients.  These findings provide new 











Figure 4.1 Cellular senescence (cellular aging). When cells are stressed by any kinds of 
genomic damages, they undergo this transition into senescence state via 
p16/Ratinoblastoma (RB), p53/p21, or others and develop Two distinct phenotypic 
changes that cells are adapted. One of them is an irreversible cellular growth arrest to 










Figure 4.2 Senescent cells secrete senescent-associated secretory phenotypes 
(SASPs). Senescent cells express tumor suppressor proteins (p16ink4a) and certain other 
markers and resist to apoptotic cell death. Senescent cells secrete SASPs into outside of 
cells including inflammatory cytokines, proteases, chemokines, and growth factors. 
These SASPs affect normal cells around senescence cells, which makes tissue function 
failed by driving inflammatory environment of tissues and subsequently affect tissue 







Figure 4.3 Kinetics of SnCs development in surgically-induced OA and effect of 
GCV-induced SnC clearance on OA disease progression in C57BL and p16-3MR 
mice. (a) Diagram depicting the p16-3MR transgene. (b) p16-3MR mice received vehicle 
(Veh, 10 μl saline) to the ACLT-operated or sham-operated knee by IA injection 8 days 
after the surgery for 5 consecutive days, with a 2nd treatment 21 days after post-surgery 
for 5 consecutive days. Shown are representative images of mice 28 days post-surgery 
and quantification of luminescence (in arbitrary units, A.U.) at the indicated time. n = 4 
for each group. Scale bar, 2 cm. In c–g, we administered two cycles of GCV for 5 
consecutive days (1 mM in 10 μl saline) starting at day 8 after surgery in p16-3MR or 
non-transgenic C57BL mice. (c) Quantification of mRNA expression for cdkn2a at 
indicated time and (d) cdkn1a, il6, col2a1, acan and sox9 normalized to β-actin day 28 
after surgery from p16-3MR mice articular joints that received Veh or GCV and non-
transgenic C57BL mice that received GCV. (e) Representative images of Safranin-
O/methyl green staining and (f) col2a1 immunohistochemistry. Scale bar, 100 μm and (g) 
the percentage of weight placed on the operated limb versus contralateral control limb 
and response time of mice after placement onto a 55°C hotplate. *P < 0.05, **P < 0.01, 
***P < 0.001 and N.S. (Not Significant); one-way ANOVA (Tukey’s multiple 
comparison test) for c, d; unpaired t-test (two-tailed) for g. All data are expressed as 






Figure 4.4 Clearance of SnCs by GCV reduces the development of post-traumatic 
OA. (a) Schematic of time course for experiments in b–h. p16-3MR male mice 
undergoing the anterior cruciate ligament transection (ACLT) were injected IA with 
vehicle (Veh) or ganciclovir (GCV) and evaluated as indicated. (b) Representative 
luminescence images of ACLT mice after Veh or GCV treatment on day 28 post-surgery 
(left) and quantification of the luminescence (right) at the indicated time (in arbitrary 
units, A.U.). Scale bar, 2 cm. (c) Quantification of mRNA expression for cdkn2a in the 
articular joints treated on day 28 post-surgery. (d) Quantification of mRNA expression 
for cdkn1a, il1β, mmp13, col2a1, acan and sox9, normalized to β-actin in joints from no 
surgery, sham operated, and ACLT mice treated as indicated. (e) Representative images 
of HMGB1 (brown, closed arrowheads) and p16INK4a (brown, open arrowheads) 
immunostaining and Safranin-O/methyl green in p16-3MR mice. f, femur; t, tibia; m, 
meniscus. Scale bar, 100 μm. (f) Quantification of non-SnCs with positive nuclear 
HMGB1 and SnCs with positive p16 INK4a in articular cartilage. (g) The medial tibial 
plateau joint score in p16-3MR mice, based on the OARSI scoring system. (h) The 
percentage of weight placed on the operated limb versus contralateral control (top) and 
response time of mice after placement onto a 55°C hotplate (bottom). All data are 
expressed as mean and each data point represents an individual mouse. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001 and N.S. (Not Significant); one-way analysis of 
variance (ANOVA) with Tukey’s multiple comparison test for c, d; two-tailed t-test 




Figure 4.5 The presence of SnCs in the synovium and infrapatellar fat pad, and 
characterization of subchondral bone changes in p16-3MR mice after vehicle or 
GCV-treatment.  (a) Representative images of p16INK4a-positive SnCs in the synovium 
and infrapatellar fat pad. Scale bar, 100 μm (b) Scores for osteophyte formation and 
medial tibial bone loss. (c) Representative images of osteocalcin. There was an increase 
in abnormal osteocalcin-positive osteoblasts (arrows) in the marrow area of the tibial 
subchondral bone are increased in abnormal in Veh, GCV and UBX0101-treated p16-
3MR with ACLT surgery. In contrast, these cells were located on the bone surface of 
sham-operated controls. Scale bar, 100 μm (d) Quantification of mRNA expression for 
runx2 and bglap (osteocalcin) as bone formation markers and ctsk, rankl, and opg 
(osteoprotegerin) as bone turnover markers normalized to β-actin in joints. In (b) and (d), 
*P < 0.05, **P < 0.01, and N.S. (Not Significant); unpaired t-test (two-tailed) for b; one-
way ANOVA (Tukey’s multiple comparisons test) for d. All data are expressed as mean 





Figure 4.6 UBX0101 dose–dependent elimination of SnCs induced by post-traumatic 
OA in p16-3MR mice and resulting changes in progression of post-traumatic OA. 
(a) Representative whole body luminescent images of vehicle (Veh) or 0.2, 1, and 5 mM 
of UBX0101-treated p16–3MR mice 28 days following IA injection once every two days 
over 2 weeks starting 14 days post-surgery (left). Quantification of luminescence (right). 
Scale bar, 2 cm. (b) Quantification of mRNAs expression for cdkn2a, cdkn1a, mmp13, 
il1β, col2a1, acan, sox9 and runx2 normalized to β-actin. (c) Representative images of 
Safranin-O/methyl green and comparison of Veh or 0.2, 1, and 5 mM of UBX0101-
treated p16–3MR mice knee joints by OARSI grade. Scale bar, 100 μm. (d) Weight 
bearing test (top) and (e) hotplate analysis (bottom) upon UBX0101 treatment. (f) Scores 
for osteophyte formation and local medial tibial bone density on day 28 after surgery. *P 
< 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and N.S. (Not Significant); one-way 
ANOVA (Tukey’s multiple comparisons test) for b; unpaired t-test (two-tailed) for a and 







Figure 4.7 Local and blood pharmacokinetics (PK) of UBX0101 after IA injection.  
C57BL mice were injected IA with 1 mM UBX0101 (in 10 μl of saline per knee, n = 2 
mice per time point).  The initial dose of UBX0101 falls below the IC50 1.5 hours 
following IA injection.  Approximately 1/30th of the initial dose reaches the circulation 






Figure 4.8 Efficacy of increasing UBX0101 injections on OA progression.  C57BL 
mice that underwent the ACLT in one rear limb to induce OA were treated every other 
day with vehicle (Veh) or different numbers of UBX0101 IA injections (1 mM in 10 μl 
saline, 1 to 6 injections) for 2 weeks starting 14 days post-surgery.  (a) Quantification of 
mRNA expression for cdkn2a, cdkn1a mmp13, il1β, col2a1 and acan normalized to β-
actin in joints 28 days after ACLT; n = 2 for each group. No statistical analysis.  (b) The 
percentage of weight placed on the operated limb versus the contralateral control limb, 
and (c) response time after placement on a 55°C platform on day 28 after ACLT surgery. 
*P < 0.05 and **P < 0.01; two-tailed t tests (unpaired). All data are expressed as mean 






Figure 4.9 Senescent cell clearance by UBX0101 attenuates post-traumatic OA and 
creates a pro-chondrogenic environment. (a) Schematic of time course for experiments 
in b–f. C57BL male mice that underwent ACLT were injected IA every other day with 
vehicle (Veh) or UBX0101 and evaluated as indicated. (b) Quantification of nuclear 
HMGB1-positive non SnCs and mmp13 immunostaining and (c) representative images of 
HMGB1 (brown, closed arrowheads), p16 INK4a (brown, closed arrowheads), Ki-67 
(brown, open arrowheads), and mmp13 (brown, closed arrowheads) immunostaining and 
the medial tibial plateau stained with Safranin-O/methyl green in articular cartilage from 
no surgery, sham operated, and ACLT mice treated as indicated. f, femur; t, tibia; m, 
meniscus. Scale bar, 100 μm.  (d) Quantification of mRNA expression for cdkn2a, 
cdkn1a, il6, mmp13, col2a1 and acan normalized to β-actin in joints. (e) OARSI scores 
of articular joints. (f) The percentage of weight placed on the operated limb versus 
contralateral control limb (left) and response time after placement onto a 55°C platform 
(right). All data are expressed as mean and each data point represents an individual 
mouse.  *P < 0.05, **P < 0.01, ***P < 0.001 and N.S. (Not Significant); one-way 







Figure 4.10 The PCNA-positive non-SnCs in cartilage and Ki67 positive non-SnCs 
in other joint compartments after vehicle or UBX0101-treated C57BL mice. (a) 
Representative images of PCNA expression by immunohistochemistry (brown staining at 
arrows). There were fewer PCNA-expressing non-SnCs in the articular cartilage of 
vehicle (Veh)-treated C57BL mice, whereas increased number of PCNA positive 
proliferating cells in those of UBX0101-treated mice 4 weeks after ACLT. Scale bar, 100 
μm. (b) Representative images of Ki-67 expression (brown staining at arrows). In Veh-
treated C57BL mice, fewer Ki-67-expressing cells (hyperplastic synovial membrane, 
brown staining at arrows) were detected in the synovium, consistent with the presence of 





Figure 4.11 UBX0101 treatment increased type II collagen protein but did not 
significantly reduce subchondral bone changes in ACLT C57BL mice 28 days after 
the injury. (a) Immunohistochemical analyses showed that in UBX0101-treated C57BL 
mice, increased type II collagen protein was detected relative to vehicle (Veh)-treated 
ACLT mice. Scale bar, 100 μm (b) UBX0101 treatment did not significantly suppress 
osteophyte formation and the extent of subchondral bone loss in ACLT mice. (c) 
Osteocalcin-positive cells (arrows) in tibial subchondral bone marrow collected 28 days 
after ACLT surgery and treatment with Veh or UBX0101. Scale bar, 100 μm (d) 
Quantification of the levels of mRNAs encoding runx2, bglap, ctsk, rankl and opg 
normalized to β-actin in joints from C57BL mice that received Veh or UBX0101 on day 




Figure 4.12 Long-term efficacy of UBX0101 in attenuating post-traumatic OA 
development.  (a) Schematic of time course for experiments in b e. C57BL mice that 
underwent the ACLT of one rear limb were treated with vehicle (Veh) or UBX0101 (1 
mM in 10 μl saline) once every two days over 2 weeks starting 14 days post-surgery.  (b) 
Left: Comparison of vehicle-treated and UBX0101-treated knee joints 56 or 84 days after 
surgery by OARSI grade. Right: Representative images of Safranin-O/methyl green 
staining of the medial compartment as indicated time. Scale bar, 100 μm. (c) Percentage 
of weight placed on the operated limb versus contralateral control limb (left) and 
response time after placement onto a 55° C platform (right). (d) Quantification of mRNA 
expression for cdkn2a, mmp13, il1β, il6, col2a1, acan, ctsk, opg, runx2, bglap and rankl 
normalized to β-actin in joints 56 days after ACLT. (e) Histological analysis of 
subchondral bone changes as confirmed by osteophyte formation and bone sclerosis 
score. All data are expressed as mean and each data point represents an individual mouse. 
*P < 0.05, **P < 0.01, and N.S. (Not Significant); one-way ANOVA (Tukey’s multiple 





Figure 4.13  Efficacy of UBX0101 for treating advanced post-traumatic OA. (a) 
Schematic of experiment for b–e. C57BL mice underwent ACLT of one rear limb to 
induce OA and were injected IA once every two days with vehicle (Veh) or UBX0101 (1 
mM in 10 μl saline) during 6 and 7 weeks post-surgery for 2 weeks. (b) Representative 
images of cells for nuclear HMGB1 by immunohistochemistry (left) and quantification of 
HMGB1-positive non-SnCs in articular cartilage (right). Scale bar, 100 μm. (c) Weight 
bearing and hot plate analyses on day 56 after ACLT surgery. (d) Quantification of 
mRNAs expression cdkn2a, cdkn1a, mmp13, il1β, col2a1 and acan normalized to β-actin 
in joints as indicated. (e) Representative images of Safranin-O/methyl green staining and 
OARSI scores. Scale bar, 100 μm. (f) Osteophyte formation and medial tibial bone score 
as indicated at 56 days post ACLT surgery. All data are expressed as mean and each data 





Figure 4.14 Clearance of SnCs slows the development of naturally occurring OA 
and post-traumatic OA in old mice. (a) Study design for clearance of naturally 
occurring p16INK4a-positive SnCs in INK-ATTAC female mice. AP20187 (AP) was 
administrated intraperitoneal (i.p.) twice a week starting at 12 months of age. (b) 
Representative images of Safranin-O/methyl green staining from vehicle-treated (-AP) 
and AP-treated (+AP) mice. f, femur; t, tibia. Scale bar, 100 μm. (c) OARSI grade; veh-
treated, 20, 21, 25, 28, 28 and 32-months-old; AP-treated, 21, 28, 28 and 34-months-old. 
***P < 0.001; two-tailed t tests (unpaired). (d) Representative whole-body luminescence 
images (left) on day 28 after ACLT surgery and quantification of luminescence (right; in 
arbitrary units, A.U.) at the indicated time after the surgery of 19- to 20-month-old male 
p16–3MR mice treated as indicated in Figure 2a. Scale bar, 2 cm. (e) Quantification of 
mRNA expression for cdkn2a, cdkn1a, mmp13, col2a1 and acan normalized to β-actin in 
joints 28 days after ACLT. (f) Representative images of Safranin-O/methyl green staining 
and p16INK4a (brown, arrows), Ki-67 and HMGB1 (brown, arrowheads) immunostaining 
on the articular cartilages. HC, hyaline cartilage; CC, calcified cartilage. Scale bar, 100 
μm. (g) OARSI grade. (h) The percentage of weight placed on the operated limb versus 
contralateral control (left) and response time of mice after placement onto a 55°C 
platform (right). All data are expressed as mean and each data point represents an 
individual mouse. *P < 0.05, **P < 0.01, ***P < 0.001 and N.S., (Not Significant); one-
way ANOVA with Tukey’s multiple comparison test for e; two-tailed t-test (unpaired) for 





Figure 4.15 Characterization of bone and other joint tissue changes after SnC 
clearance in naturally-occurring or surgically-induced INK-ATTAC or p16-3MR 
aged mice. (a) Subchondral bone damage scores for osteophyte formation and medial 
tibial bone sclerosis in INK-ATTAC female mice that received vehicle (-AP, n = 6) or 
AP (+AP, n = 4) according to the scheme shown in Figure 4.14a.  (b) Quantification of 
p16INK4a-positive SnCs and Ki-67-positive non-SnCs staining in articular cartilage. (c) 
Scores for osteophyte formation and medial tibial bone sclerosis and (d) osteocalcin-
positive cells in subchondral bone marrows (brown, arrows) by IHC of 20-month-old 
p16-3MR male mice with ACLT surgery treated with vehicle (Veh) or UBX0101 (1 mM 
in 10 μl saline, once every 2 days over 2 weeks starting 14 days post-surgery). (e) The 
presence of p16INK4a-positive cells in the subchondral bone marrow, synovium and fat 
pad (brown) of p16-3MR mice shown by immunostaining and their changes after 






Figure 4.16 Presence of SnCs in human healthy and osteoarthritic articular 
cartilage.  Representative images of HMGB1-positive non-SnCs (brown staining at 
arrows) by immunohistochemistry and SA-β-gal-positive SnCs expression on the 
articular cartilage. SA-β-gal-positive SnCs were observed throughout the depth of 
osteoarthritic cartilage (donor: 65-years-old, Male), but were sparsely present in healthy 
cartilage (donor: 62-years-old, Male).  A range of 7-15% SA-β-gal-positive SnCs were 
observed in primary chondrocytes isolated from healthy cartilage and 41–50% SA-β-gal-







Figure 4.17 UBX0101 clears SnCs by inducing apoptosis and improves cartilage 
tissue forming ability of chondrocytes from human OA tissue.  (a) Schematic for 
monolayer experiment in b–e. (b) Quantification of SA-β-gal-positive cells and the 
percentage of live (gate Q2: PI-Annexin V-), apoptotic (gate Q3: PI-Annexin V+ and Q4: 
PI+Annexin V+), and dead (gate Q1: PI+Annexin V-) SnCs in monolayer cultured human 
OA chondrocytes treated with vehicle (Veh) or 43 μM of UBX0101. Representative 
images of cells with nuclear HMGB1 (red) by immunostaining. (c) Representative flow 
cytometric plots to measure apoptosis from 3 independent experiments. (d) Western blot 
analysis of cleaved caspase3 (cCasp3) and actin in human OA chondrocytes 18h, 1 and 2 
days after incubation with Veh or 43 μM UBX0101. (e) Quantification of mRNAs 
expression for cdkn2a, mmp3, il1β, il6 and mmp13 normalized to β-actin in cultures 
described in (a); n = 3 for each group. (f) Representative 5-ethynyl-20-deoxyuridine 
(EdU) staining (left; green) and quantification of the percentage of EdU-positive cells 
(right) after removing SnCs from human OA chondrocyte cultures by UBX0101; n = 5 
for each group. (g) Schematic for 3D cultured pellets experiment in h-j. (h) SA-β-gal 
(left) and sectioned images (right) immunostained for p16INK4a, mmp13 and col2a1 and 
stained for Safranin-O of 3D cultured pellets of the human OA chondrocytes treated with 
Veh or 43 μM of UBX0101; n = 3 for each group. (i) Quantification of mRNAs 
expression for cdkn2a, mmp3, il1β, il6, col2a1, and acan normalized to β-actin; n = 3 for 
each group. (j) DNA contents normalized to dry weight and sulfated 
glycosoaminoglycans (sGAGs) normalized to the DNA content. In (e–f) and (i–j), data 




Figure 4.18 Dose-dependent elimination of senescent chondrocytes isolated from 
human OA tissue by UBX0101 treatment. (a) Schematic of experiment for b–c. (b) 
SA-β-gal positive cells were quantified 2 and 8 days following treatment with increasing 
concentrations of UBX0101. A dose of 43 μM and a short treatment time (2 days) 
selectively eliminated SA-β-gal positive senescent chondrocytes. Data are averages ± 
S.D. *P < 0.05, **P < 0.01, ***P < 0.001 and n.s (Not Significant); two-tailed t tests 
(unpaired).  n = 5 for 0, 8.6 and 12.2 μM; n = 6 for 34.4 and 43 μM.  (c) Representative 
images of cells with SA-β-gal staining. Scale bar, 100 (d) Western blot analysis of p21 
and GAPDH in OA chondrocytes 2 days after treatment with vehicle or 43 μM UBX0101. 
(e) Activated caspase-3 (cCasp-3) and actin in healthy chondrocytes (Non-SnCs) and 
actin in OA and healthy chondrocytes 1 or 2 days after treatment with vehicle or 43 μM 
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